Data mining and data integration in biology by Ólason, Páll Ísólfur
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 17, 2017
Data mining and data integration in biology
Ólason, Páll Ísólfur; Brunak, Søren
Publication date:
2008
Link back to DTU Orbit
Citation (APA):
Ólason, P. Í., & Brunak, S. (2008). Data mining and data integration in biology.
Fyrir Helenu Evu og O´lo¨fu So¨ru
i
ii
Foreword
This thesis is the result of my stay at the Center for Biological Sequence Anal-
ysis, BioCentrum at the Technical University of Denmark. My Ph.D. work was
made possible by grants from the BioSapiens Network of Excellence, FP6 and
the Danish Platform for Integrative Biology with Focus on Systemic Proteomics
- DPIP. The work was carried out under the supervision of Professor Søren
Brunak with the help of a number of people.
Pa´ll I´so´lfur O´lason, Reykjav´ık, March 2007
iii
iv
Acknowledgments
They say that Ph.D. work is a test of one’s abilities to work independently, but
I would never have finished without the help of a number of people. To name a
few of them:
My supervisor: Professor Søren Brunak. Many thanks to him for giving me
this opportunity. Always full of novel ideas and inspiring his troops to
think in new ways, he deserves a lot of credit.
BioSapiens NoE, especially my DAS and ENCODE collaborators. The work
associated with this huge proteomics consortium has been both successful
and enjoyable.
Funding agencies. The Danish Platform for Integrative Biology, DPIB, and
the Danish National Research Foundation. Thanks for your generousity.
My officemates Olga Rigina and Hans-Henrik Stærfeldt. I felt a bit like James
Bond when told that I would be sharing an office with a mathematician
from Siberia and a super-hacker. Olga and Hans-Henrik, thank you for all
your support.
Co-authors of my papers all 50+ of them, look inside for names.
The CBS administrators. Lone, Johanne, Anne, Dorthe, Marlene, Hanne.
You keep CBS running, thanks for all your help.
The system and database administrators. Kristoffer Rapacki, Hans-Henrik
Stærfeldt, Peter Wad, Olga Rigina. Thanks for keeping things running and
for all your technical wisdom.
The disease gene finding group. Exciting project, great people!
v
Thomas Sicheritz-Ponte´n. My collaborator on protein-protein interaction
prediction, a sometimes depressing and ultimately unrewarding project.
Thomas was also the only person to proofread this thesis, but he will get
a reward for that. Thanks Thomas!
The Integrative Systems Biology group. The coolest group, by far ;)
Comrades made through travels, coursework, meetings and projects. My stay
at CBS has allowed me to meet and interact with so many great people
I don’t know where to start. Kasper, Olof, Ulrik, Thomas Skøt, Thomas
Ponte´n, Rodrigo, Zenia, Peter Hallin to name just a few. I know there are
many more but it would take pages to put everyone here. Thanks for all
the good times.
Kristoffer Rapacki. The official welcoming committee at CBS, Kristoffer strives
to make everybody feel at home and always has time to help, despite being
extremely busy. Thanks for all your help, humour and friendship.
CBS is a wonderful place to work. Thanks to all you people who make it so.
Open source software authors. This work and this thesis would not have
been possible without the generousity of the open source software com-
munity.
My family. My lovely wife O´lo¨f Sara and my daughter, Helena Eva, my great-
est source of inspiration, she always helps me put things in perspective.
They gave me the energy to finish writing this thesis while working full
time on a new job and refurbishing our new apartment in Iceland.
vi
Abstract
Last decade saw an explosion in DNA sequencing and the draft version of the
human genome. Now, proteomics is experiencing the same growth. With pro-
teins being the functional elements of living cells, high-throughput proteomics
promises more understanding of cellular functions and the interactions between
molecules, the essence of systems biology.
Internet technologies are very important in this respect as bioinformatics labs
around the world generate staggering amounts of novel annotations, increasing
the importance of on-line processing and distributed systems.
One of the most important new data types in proteomics is protein-protein in-
teractions. Interactions between the functional elements in the cell are a natural
place to start when integrating protein annotations with the aim of gaining a
systems view of the cell. Interaction data, however, are notoriously biased, er-
roneous and incomplete. They also necessitate new ways of data preparation as
established methods for sequence sets are often useless when dealing with sets
of sequence pairs. Therefore careful analysis on the sequence level as well as the
integrated network level is needed to benchmark these data prior to use.
The networks, which emerge when interaction data are integrated, form a skele-
ton to which we can attach other annotation types. Then, using graph theoret-
ical methods, we can identify network structures and infer annotations across
the links of physical interactions, thus defining novel functional modules, or in
the case of dysfunction: disease modules and genes.
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Dansk Resume´
I den s˚akaldte “post-genomic” æra vi oplever nu, er den humane genomsekvens
kendt og sekvenseringsprisen falder hvert a˚r. Nu st˚ar kapløbet om at finde sam-
menhængen mellem de forskellige sekvensprodukter, systembiologiens største
m˚al.
Proteiner er organismers byggesten, og deres egenskaber, funktion og veksel-
virkninger er meget vigtige i denne sammenhæng. Integration af protein anno-
teringer fra hele verden er nødvendig for udvikling inden for systembiologi. Pro-
jekter ligesom ENCODE arbejder p˚a koordinering af denne slags annoteringer
og analyse af de forskellige produkter af de samme gener.
Internetteknologier er meget vigtige i denne sammenhæng, da bioinformatik og
sek vensanalyse fremstiller utrolige datamængder. Dataproduktionen overstiger
faktisk Moores lov om vækst af dataprocesseringskapacitet, hvilket gør at dis-
tribuerede systemer og real-time processering er at foretrække frem for statiske
databaser i mange tilfælde.
En af de vigtige nye datatyper inden for cellebiologi er protein-protein vek-
selvirkninger. Disse data beskriver proteiners samspil og komplekse funktion i
cellen og er derfor en naturlig byggesten for systembiologien. Disse data er dog
fulde af støj og meget inkomplette. Derfor er det vigtigt at udvikle metoder til
op rensning af data og forudsigelse af ukendte vekselvirkninger, hvilket dog ikke
er lige til, da vekselvirkningsdata har protein-par som grundenhed, hvilket gør
alle algoritmer mere komplekse og opbevaring samt analyse langt besværligere.
De netværk, der opst˚ar ved integration af vekselvirkningsdata, danner et skelet
for de funktionelle elementer, komplekser og pathways i cellen. Grafteoretisk
analyse af protein netværk er et vigtigt værktøj til forst˚aelse af cellen som et
system. Dette kan indebære teoretiske overvejelser omkring tæthed og kon-
nektivitet af proteiner, samt praktiske forbindelser mellem sygdomsgener der
optræder sammen i kompleks eller pathway. Integration af data, der beskriver
funktion, phenotype og genetiske fejl, kortlagt p˚a dette skelet af vekselvirkn-
ingsdata kan hjælpe os med at prioritere kandidatgener for sygdomme, hvilket
kan føre til nye lægemidler i bekæmpelsen af medfødte sygdomme.
v
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Chapter 1. Introduction
1.1 From genomics to functional genomics to
systems biology, but not back again
As I attended an “Introduction to Bioinformatics” course in 2001, two articles
announced that the sequencing of the human genome had been finished. So why
on earth did I choose this field of research and occupation, when the blueprints
to life had already been uncovered?
Well, uncovered does not mean understood. As one evil mastermind1 once said
to 007: “The key to a great story is not who, or what, or when, but why”. Our
DNA blueprints differ only to an amount of a tenth of a percent, all humans
have the remaining 99.9% in common. How then do we explain our different
appearances? I and my 4 siblings (3 brothers, 1 sister) were all born with blond
hair, why is it that only I and one of my brothers now have dark hair, while the
others still have blond hair, and what triggered the change in hair color? Why
is it that only I am starting to get gray hairs? Actually, I think this thesis holds
the answer to that one, although not literally.
Even though a draft version of the human genome has existed for several years
now, that has not meant the end of sequencing. On the contrary; we are pro-
ducing sequences at an unprecedented rate. The human genome sequence is
still incomplete and the assembly of the shorter sequence fragments into larger
ones is tricky, so huge chunks of DNA are often shuﬄed around between builds
of the genome. Apart from humans, other organisms are continuously being
sequenced, with over 30 (partially or fully) sequenced eukaryote genomes avail-
able in the Ensembl browser (www.ensembl.org) at the time of writing, and
the number of sequenced bacteria reaching into the hundreds. Excitingly, only
a few days ago it was reported that Craig Venter - one of the people behind the
privately funded version of the human genome [274] - and colleagues have pro-
duced an astonishing 7.7 million sequence reads from ocean samples collected
around the world, most of them novel sequences. These sequences may assist in
as different fields as antibiotics production and the search for new, sustainable
energy sources [226]. Sequencing is being performed on a gigantic scale, and
large scale proteomics analysis has only just begun. This is only the primary
sequence data. Such data have now been produced for 30 years and polymerase
chain reaction (PCR) and automatic sequencing make this task a breeze. It is
the functional analysis of these sequences takes most of our time.
1Elliot Carver (Jonathan Pryce) in Tomorrow never dies (1997).
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again
For every new stretch of sequence deposited in the data banks, one can antic-
ipate that hundreds of analysis reports are made; sequence similarity reports,
predictions of genes, introns, exons, promoter regions, the list goes on. And this
is only for the primary DNA sequence. The central dogma of flow of hereditary
information is DNA to RNA to protein, and this is not a one to one relation-
ship. A single gene can yield a number of splice variants and when you throw in
protein post-translational modifications, native and chaperone-assisted folding,
domain and motif definitions, expression, physical and chemical properties, the
possibilities for analysis are endless.
Figuring out how these individual components function and interact is the key
to the great story, the why. This thesis is an attempt to describe a number of
hows and then assemble those to answer a couple of whys. But don’t worry,
there are not that many answers in here, and no suggestions about the meaning
of life.
The big why is to understand the biology of organisms and cells, why these
complex systems have evolved the way they have, and for practical purposes: to
understand why things sometimes do not function as they should. The key to
this understanding is to figure out how these systems, and their subparts work.
To integrate all the data on the individual components of the cell and and put
them in a cellular, physiological, and evolutionary perspective2.
Combining all these small hows into larger hows and, eventually, whys is pretty
tricky and this is where bioinformatics comes into play. Integrating data in
biology is not a mere punch on the stapler. The, sometimes ridiculous, amounts
of data being generated are well beyond any simple staple to penetrate. And
even if they were not, the diversity of the data is so great that simply collecting
and stacking data is not meaningful. One has to churn through the endless flow
and try to sort, shuﬄe, filter and index the relevant stuff. Hopefully one has
something of interest to report at the end.
2When is a relevant question to ask, but at what timescale? If we are talking life in
general, then evolution certainly is a huge and important field within bioinformatics and
biology. Looking at shorter time spans, the cell cycle, development, apoptosis, to name a
few, are events with a temporal facet, although one may argue that this aspect only reflects
the how and the why. The only when to be addressed in this thesis is the deadline for its
submission.
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1.2 The problem: which bread crumbs to fol-
low?
Imagine that you are employed at a record store and you unpack a box of
compact discs. You need to register the CD in the store’s computer system
along with a short description and put the CDs in the right rack (pop, rock,
country, classical etc.) in the store. How do you proceed? The obvious choice
is to simply listen to the CD and describe and classify it accordingly, and this
is what the first music shop owners were forced to do. This however is time
consuming and requires expensive equipment. As a short cut, many would
simply look for similar CDs; has the artist released a CD before? And if so,
is it already registered and described in the computer? If we are in luck, the
artist already has been described in the system and we can place the new CDs
besides his/her earlier work in the shop. If this is the artist’s first album, we
might look for subtle clues on the CD cover: five young guys standing in line
probably indicates a “boy band”, big cars with shiny wheels and girls wearing
bikinis on the hood is a dead giveaway for hip hop, a swan on a lake suggests
Tchaikovsky and so on. Thus, we may integrate data to make our lives easier.
The Internet is very valuable in this respect. It is not always trustworthy but
usually it gives us the information we need in a few clicks of the mouse.
Sequence analysis has gone through several phases. Ever since the data format,
DNA, was described about 50 years ago, we have been seeking to understand
these blueprints for life. At first, we had to build equipment to “play” the tracks
and build up a database of different sequences. There was no Internet to help
us look up artists and new releases. Today, we have indexed so much, that it
usually is not necessary to listen to the tracks yourself, it is quicker to just look
up the new tracks by similarity in the database and copy/paste its annotations.
Sure you get new, novel tracks in now and then and need to examine them
manually to be able to classify and register, but this is usually fun and exciting
work. Now, the focus is on making the shop more accessible to the customers:
you want to cluster the similar categories together, cater for specific needs, allow
for new formats of entertainment, to sell re-mixes, posters and t-shirts alongside
people’s favorite music, to give people the whole picture instead of just plain
CDs. Ensembl’s BioMart is a good example of such an approach in sequence
analysis. Given an organism, you can download, along with the primary DNA
sequence, dozens of annotations to attach to the sequences, ranging from gene
synonyms to functional classification of proteins. The problem is not lack of
4
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data, but rather to figure out what data are relevant to answer your particular
question.
The field of bioinformatics has shifted focus from searching to understanding to
putting things in perspective; from sequencing to functional analysis to systems
biology. Even though systems biology is a relatively new phrase, the concept is
not and tasks in systems biology are mostly the same as the tasks in functional
genomics, which was a buzzphrase 5 years ago. Performed at a larger scale
maybe and with a more global perspective, but at the core, functional analysis
of the individual components is still the way to understand the system.
During the initial sequencing era, it was discovered that man, the pinnacle of
intelligent life has blueprints as about as complex (as far as count of known genes
is concerned) as the nematode C. elegans. We are realising that the phenotypes
of organisms are the product of more than the bare count of genes, but rather the
amount of splice variants and even the number of times the genes are transcribed.
Indeed, new results indicate that the quantity in which genes are transcribed and
translated is a key to our phenotype, whether this quantitative variation stems
from repeats in the DNA itself [218] or from difference in gene expression [245].
Apart from variability in sequence and expression, it is clear that most or all
gene products perform their tasks as a part of a larger unit. Protein complexes
assemble and disassemble at specific points in time and space [61] and metabolic
and signaling pathways are complex chains of reactions and regulation. Figuring
out the link between the components in these complex systems, their control and
function, then the link between the modules and the phenotype of organisms is
the ultimate goal.
Today there is no shortage of information to annotate primary sequences. At
the Center for Biological Sequence Analysis (CBS) website alone (http://www.
cbs.dtu.dk), there are almost 50 tools to analyse primary sequences, either
DNA or proteins. The hard part is to decide what information to integrate, to
find the relevant data or tools (usually on-line) and finally integrate them in a
meaningful way to answer some of the whys.
The phenotypes of inherited diseases are caused by (yet) unidentified genes in
most cases, and although a single disease gene can be identified in some cases
like cystic fibrosis and Huntington’s disease, most cases seem to have a much
more complex explanation than a mutation in a single gene. Even in cases
where disease susceptibility genes are known, the majority of drugs, designed to
target those genes (or, rather, their products), fail clinical trials [90]. Usually
because of unpredictable reactions with other components in the cell, disrupting
5
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the delicate balance that these components display in vivo. When we have
learned how those components function and link to each other, we can start
modeling the effects of drug leads in cellular systems, and in time, high resolution
bioengineering will perhaps enable us to design drugs for each individual, based
on their genotype.
So, we have a huge amount of primary sequence data, and for each stretch of
sequence we have virtually unlimited annotation sources. Our task is to figure
out where to start; to find out which path leads to understanding of the functions
and dysfunctions of cells and organisms. The perspective we wish to achieve is
systems biology - a map of the forest - but where do we get it?
1.3 Our solution: the interactome as the back-
bone of systems biology
The recent interest in systems biology has been sparked by the availability of
high-throughput data, especially protein-protein interaction (PPI) data. Several
proteome-wide interaction studies have been performed and published in the last
5 years [127, 266, 98, 119, 97]. Figure 1.1 shows the annual amount of papers
indexed by PubMed containing the phrases “protein interaction” or “systems
biology”. Publications containing these phrases are appearing at a rate far
surpassing the normalised growth of PubMed databases. It is not a coincidence
that PPI data and systems biology have come up in the world together. Systems
studies are all about connecting components on some level and as proteins are
the cell’s functional components, physical interactions are a perfect thread to
connect proteins in a systematic fashion.
The emerging network of protein-protein interactions, the interactome, makes
a ideal scaffold to which we can glue other annotation types in order to build
high-level models of reactions, complexes, pathways, and ultimately, the entire
cell [126]. The reason that PPI networks make such an excellent scaffold to
build integrated analysis upon is that PPIs lie at the heart of most of the cell’s
functionality. Whether it is replication, transcription, translation, biosynthesis,
degradation, signaling, immune response. Proteins are the cell’s workhorse, and
to understand the cell, we must understand the functions of proteins.
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Figure 1.1: Search results for the phrases “protein interaction” and “systems
biology” in the PubMed index. The number of publications containing “protein
interaction”has been increasing linearly for the past decade, and following closely,
papers mentioning “systems biology” are now appearing at a similar rate. The
red line shows the growth of PubMed databases normalised to 100 at the year
2000, included to give a general idea about the publication rate in life sciences.
Publication rate of papers containing either of the above mentioned phrases far
exceeds normalised PubMed growth.
PPI data are not perfect, they bring a number of analysis difficulties, as they
consist of sets of pairs instead of single proteins. They are also noisy, hard to
interpret definitively and incomplete, especially for H. sapiens [276].
Having integrated and analysed the interaction data, we want to attach other
annotations onto the skeleton of protein interactions. As most annotations come
from on-line sources, it is important to know where to look for such data and to
be able to trust these. Formatting data using standard specifications is a great
help in these situations, easing the workload considerably. These standards need
not be technically complex. The most important thing is for everybody to decide
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on one standard, because what good is having a better standard specification if
your lab is the only lab using it?
One of the less frequent data types described later in this text is phenotype
data, most of which is on the form of free text, in contrast to most annotation
types described in here. There is room and need for much improvement here as
systems biology is finally allowing us to use computers to bridge genotype and
phenotype in an automated way.
Data integration in biology is still a tough task. Even though chapter 2 describes
some advanced ideas and technologies for sharing and integrating data, most
data out there needs to be manually glued together for special purpose research.
The research papers included in chapters 3 and 4 have all required a huge amount
of manual labor to massage the data into results.
1.3.1 Components vs. systems
Having said that the key to understanding the system is to understand the
individual components, a systems view of cellular components is quite different
from focusing on the details of the individual sequences. Usually a reductionist
view is applied, and a perfect understanding of the image on the individual
pieces may not be necessary, but we need to make sure they fit together if we
are to finish the puzzle.
Molecules in the cell have finite life spans and those molecules (sequences, hor-
mones, nutrients and other) are not the focus of systems biology, their collabora-
tive functions, interactions and regulation is. The components come and go but
the system and its subsystems stay the same just like a carpenter still views his
hammer as the same he bought 20 years ago, despite having replaced the handle
three times and the head once. Emergent properties are the properties which
arise as data pile up and get integrated, the properties of the system, rather
than components. Regardless of emergent properties now being the focus of
attention, we still need bottom-up approaches like sequencing and functional
analysis of individual sequences because we still do not fully understand these
components.
Sequencing is not as expensive or time consuming as it used to be. Proteomics
research, on the other hand, is very challenging. The vocabulary of 20 amino
acids instead of 4 nucleotides allows for much more complex chemistry. Throw
in folding, alternative splicing, post translational modifications, wide dynamic
8
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range and tissue, developmental and temporal specificity and we realise that
“genes were easy”3. Despite not being as scalable and easily automated as
DNA sequencing, proteomics is still moving steadily towards high-throughput
techniques with “labs on a chip” starting to replace slow, labor-intensive and
costly biochemical assays [205, 264].
But experimental techniques are not enough. Large scale data integration that
systems biology demands, cannot happen within an isolated lab. With the
latest and greatest mass spectrometry equipment and trained staff only being
within reach of the best funded labs, data must be made available for colleagues.
Guidelines for raw data sharing, like the Bermuda rules [178] for the human
genome project, should be adopted for proteomics.
1.4 Directions to the thesis
This thesis is built as an attempt to describe a move from analysis of individ-
ual components, proteins in my case, although the concepts of genes and gene
products certainly could be (and are) used interchangeably in most cases, to an
integrated view of all known components in a system.
In today’s post-genomic era, we are certainly moving away from the primary
sequence in bioinformatics, the question is how far away? Systems biology was
born as a result of high-throughput technologies where thousands of components
are analysed at once. The transition to high-throughput methods requires a new
way of thinking, new statistics, new algorithms, even new naming schemes, as
simply identifying the right sequence in todays monstrous data warehouses is a
formidable task. This thesis is about data integration and the structure of the
text reflects the workflow.
We start with simple sequences, analysing those with numerous tools in a bottom
up fashion; on the desktop, in the lab and most importantly today: on line. We
describe the diversity of sequence data and metadata and current work to keep
track of it all.
Next, we start putting the protein pieces together, trying to understand how the
components interact, and to predict their interactions from primary sequence
and domain composition. As we use interactions a skeleton to attach other
3The Human Proteome Organization (HUPO) held its inaugural meeting in 2001 under
the slogan “Genes were easy”.
9
Chapter 1. Introduction
annotations on, it is important to get this “infrastructure” of systems biology
right. PPI data are notoriously noisy and incomplete. Analysis and prediction
of PPIs is difficult for many reasons: non-interacting pairs to use as contrast are
hard to define, algorithms commonly used for redundancy reduction, similarity
searches etc. are designed for sets of single sequences, not sets of sequence pairs.
When the components have been connected, a network emerges and we change
our perspective from local to global, using top-down approaches such as network
modeling and global trends, such as clustering, to annotate individual compo-
nents and functional modules, where the individual components work together
on a cellular task as a whole. These functional modules, complexes or path-
ways, sometimes break down, in which case our network analysis of annotations
attached to the skeleton of physical interactions may help us identify the faulty
component. Identifying the faulty component(s) is the first step to mending
a dysfunctional system. Thus we can trace correlated disease phenotypes over
links in the network of physical interactions and assign the target proteins as
products of potential disease genes.
10
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In this first chapter of this thesis about biological data integration, I wish to
introduce some of the issues in biological data management, with a special focus
on protein annotation data. More recent data types - the omics data - are also
mentioned. The impact of the Internet on sequence analysis will be discussed,
as data integration would be non-existing without publicly available data sets.
Finally I will share some thoughts about further developments I envision for
data management within on-line biology.
2.1 Biological data
The complexity of molecular biology and our analysis thereof make it hard for us
to disseminate the information we have compiled, and to receive, comprehend,
and integrate information from others. Two main problems hamper biological
data sharing on a global scale:
Data accumulation: The growth rate of biological databases is incredible, its
doubling rate surpassing Moore’s law 1, which highlights the importance
for the field of bioinformatics to keep up the pace.
Data diversity: Biology is a huge field and there is simply an infinite number
of data types. To make things even“worse”, new data types are continually
being made as new experimental designs see the light of day. This makes it
hard come up with standardised data sharing formats and infrastructure.
As the world wide web (www) and other technical infrastructures evolve, the
first mentioned “problem” of data growth, while still a significant one, must be
accepted as a consequence of a productive scientific community and countered
with a similar advance in hardware as well as software.
The community’s shortcomings in dealing with diversity, however, only become
more and more emphasised as we move further towards comparative genomics
and systems biology.
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Figure 2.1: Left: Growth of the UniProt databases: TrEMBL is a database of
translated nucleotide sequence entries in EMBL, with automated annotations
while Swiss-Prot is a manually curated database with high-confidence annota-
tions. The size is measured as total number of sequences. Right: Each year
the Nucleic Acids Research magazine publishes a database issue describing new or
improved databases pertaining to sequence analysis. The plot shows the number
of databases published each year.
2.1.1 Database growth
The first repositories of sequence data only held a handful of sequences or struc-
tures [26, 25], and they were released in paper format or via slow telephone con-
nections if you were so lucky to have a computer in you lab. Today the picture is
quite different; as the cost of sequencing drops, sequence databases are overflow-
ing with data and submission rates are increasing. Indeed, the cost of sequencing
has fallen more than ten-fold in the last decade, and now plans and funding are
available for approaches, that will make an entire human-sized genome sequence
available for $1,000 (http://www.genome.gov/15015208). Figure 2.1 shows the
size of the UniProt databases [288], where TrEMBL is a database of translated
nucleotide sequences from EMBL and Swiss-PROT is a manually curated pro-
tein database. It is clear that the manual curation effort is lagging about an
order of magnitude behind the rate of sequence submissions. This demonstrates
the need for high performance computing within biology, as well as high confi-
1Moore’s law is the empirical observation that the complexity of integrated circuits, with
respect to minimum component cost, doubles every 24 months. It is attributed to Gordon E.
Moore, a co-founder of Intel [283].
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dence, automated annotation strategies. Human effort alone will never keep up
with sequence submissions.
The cost of computation rarely grows linearly with the size of input data; rather
it grows polynomially or exponentially. In practice, a doubling of the input
search database means that the BLAST sequence alignment algorithm [6] needs
8 times the computational time as before the input doubling, because it has n3
complexity 2 with respect to input data.
Most bioinformatics groups provide some sequence analysis tools and many offer
the annotation results as specialised data sets and on-line databases. Therefore
there has been an explosion in the number of databases published in the field.
Nucleic Acids Research publishes an annual database issue which describes new
or improved sequence analysis databases. Figure 2.1 shows the steady increase
of new databases published in the issue since 2001.
The growing number of databases not only demonstrates the growing amount
of data in biological databases, but also the growing number of new data types
in biology; next section’s subject.
2.1.2 Data types
As shown in the last section, there is no shortage of biological sequence data
in the public domain, with databases growing at ever-increasing rates, leaving
manual curation efforts far behind. This explosive growth can only be countered
by similar performance increases in computing, as well as a continuous effort for
more efficient algorithms in bioinformatics.
Following the shift in focus from genomics to functional genomics to systems
biology, diversity in data types mirrors the advances in computational biology.
Functional genomics has given rise to a huge number of data types, both experi-
mental and computational, used to annotate biological sequences. Twenty years
ago, sequence analysis data were mostly limited to the sequences themselves.
2“The time complexity of a problem is the number of steps that it takes to solve an instance
of the problem as a function of the size of the input (usually measured in bits), using the most
efficient algorithm. To understand this intuitively, consider the example of an instance that
is n bits long that can be solved in n2 steps. In this example we say the problem has a time
complexity of n2.” “Example: Mowing grass has linear complexity because it takes double
the time to mow double the area. However, looking up something in a dictionary has only
logarithmic complexity because a double sised dictionary only has to be opened one time more
(e.g. exactly in the middle - then the problem is reduced to the half.” Taken from [282].
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During the last two decades (and even more) the Center for Biological Sequence
Analysis (CBS) and other labs have produced sequence annotations, both ex-
perimental and computational, for proteins and genes, predicting and analyzing
their chemical, structural and functional properties. At CBS’ sequence analy-
sis web page alone, http://www.cbs.dtu.dk/services, there are currently 9
DNA sequence annotation servers and 31 protein annotation servers; a glimpse
at the huge number of different analysis methods (and therefore annotation data
types) publicly available.
Moving towards whole genome or proteome analysis, several high-throughput
methods have been established. Examples of such new data types in sequence
analysis include microarrays [231], DNA chips [172], yeast two-hybrid method
[89] and complex purification followed by mass spectrometry [119, 98] for pro-
tein protein interaction data, ChIP-chip [219] for protein-DNA binding, protein
microarrays [154] etc. Adding to this complexity is a myriad of meta data, which
often accompanies lab data such as mass-spectrometry.
Today, the focus is on integrating these bits and pieces of information from
functional analysis of sequences; to assemble them into a coherent view.
Omics data
Since the completion of the human genome drafts in 2001 [162, 274] the number
of publications containing the phrase“systems biology”has exploded [62]. Along
with systems biology come the omics data, used to refer to some sort of data in
their totality. First there were genomics data, closely followed by proteomics.
Following those came metabolomics, transcriptomics, nutriomics, interactomics,
phenomics, localizomics, spliceomics, ORFeomics and more. Today, we simply
talk about omics data when referring to large scale comparative approaches,
where the entities, be it proteins, genes or nutrients, are not the focus, but
rather seen as a part of a larger picture.
It is not the aim of this document to survey biological data types exhaustively,
as that is an exercise in futility. Furthermore, such a review would soon become
obsolete as new data types are constantly emerging. My aim is simply to point
at the enormous size of the the problem facing scientists who wish to combine
heterogeneous data.
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Text mining
The integration of the diverse data types described above is difficult, but the
bulk of scientific information lies not in formatted, readily available data sets,
but rather in free text in scientific literature.
This short section does not try to give any practical introduction to the field of
text mining, which is a whole science in itself, but only to highlight some of the
tasks.
The abundance and richness of scientific literature is unfathomable and as I
soon learned during my as yet brief research career, it is impossible to stay on
top of all the information published, even within a very narrow field such as
information exchange standards in biology or protein protein interactions. The
MEDLINE biomedical literature database [198] now contains over 15,000,000
searchable abstracts and the PubMed interface at NCBI handles over 80,000,000
queries to the database every month, as seen in figure 2.2.
Figure 2.2: Medline growth. The figure shows the monthly number of queries to
Medline. Taken from: http://www.nlm.nih.gov/bsd/medline growth.HTML.
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Within bioinformatics, a growing effort is made on mining this huge information
resource and for the last 5 years a special interest group meeting for text mining
in biology, BioLINK, has been held at the largest current bioinformatics con-
ference: Intelligent Systems for Molecular Biology (ISMB). CBS has now joined
the labs that have incorporated text mining into their arsenal of scientific re-
search tools. CBS’ first steps into the field are described in the last chapter (4)
of this thesis, where our attempts at candidate gene prioritisation are described.
Literature mining may be performed in various ways and with various tools,
ranging from simple string matching and word vector similarity measures to
natural language processing and machine learning Some approaches aim at in-
dexing the text for subsequent lookup and extraction, such as a search engine
on the Internet might index on line documents. These approaches are termed
information retrieval (IR).
A special sub-problem of scientific text mining is to recognise the entities (ER)
that are annotated or analysed in the text; the components as I have chosen
to call them in this chapter. Genes and proteins usually have several different
names which can incorporate lower- and uppercase letters, numbers and even
symbols.
More advanced techniques are required when information extraction (IE), such
as deriving relationship between entities (e.g. “protein A phosphorylates protein
B” or “genes X and Y were not found to be co-expressed”), is attempted, as it
is much more complex to extract semantic meaning from documents than to
simply scan them for keywords as is most often the case in IR. An extension
to relationship derivation is hypothesis generation, where de novo knowledge is
sought from text. Swanson, an innovator in the field of hypothesis generation,
constructed successful models as early as the mid eighties [254, 255]. Despite
the fact that Swanson’s models were assembled by himself and not automat-
ically generated by a computer, his work shows how implicit connections can
be made on the basis of seemingly unrelated literature. ARROWSMITH, an
automated tool, partly based on Swanson’s work has been publicly available
since 1998 [238]. Swanson is still active in the field and recently published an
article suggesting a relation between atrial fibrillation and overtraining-induced
inflammation [256]. Excellent reviews by Jensen et al. [136] and Cohen & Hersh
[54] describe biomedical literature mining and current approaches to it more
thoroughly.
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2.1.3 ENCODE
There has been a recent surge in efforts, not only to annotate the primary se-
quence data in databases, but to analyse variation in the sequence data, leading
to even greater complexity in the information space of bioinformatics. Such
efforts include the HapMap project [1] to map single nucleotide polymorphisms
(SNPs) and the ENCODE project, which aims at functionally annotating 1% of
the human genome to set the standard for methods and tools chosen to analyse
the remaining 99% [58].
The data and analyses produced by such projects may not just enhance our
current view of biology, but even paradigms such as the “one gene/one enzyme”
theory3 may be up for review as Carninci et al. conclude that most genes may
have several gene products, many of which seem radically different and most
likely have different functions [43].
Within the BioSapiens Network of Excellence, several European bioinformatics
groups have compiled annotations for the ENCODE data and these have been
integrated and published as described in the next section. The paper shows
the diversity of annotations possible and how variation within loci needs to be
taken into account when assigning function to genes and proteins. The methods
used to integrate the data will be described later in section 2.3. The following
paper serves as a showcase of the diversity of data types within proteomics and
bioinformatics as well as that the huge amounts of sequence data produced are
now being expanded with variation data on individual genes and proteins.
3Put forth by Beadle and Tatum and taught (in a refined version) in most textbooks on
biochemistry.
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Abstract
Alternative pre-messenger RNA splicing is a mechanism that enables many genes
to generate more than one gene product. Alternative splicing events that affect
protein coding regions have the potential to create new protein functions and
alternative splicing has been suggested as one explanation for the discrepancy
between genome size and functional complexity. Here we carry out a full-scale
study of the alternatively spliced protein isoforms annotated in the ENCODE
pilot project. We find that alternative splicing is more frequent than commonly
suggested in human genes. However, we also demonstrate that many of the
potential alternative gene products will have markedly different structure and
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function from their constitutively spliced counterparts. For the vast majority of
these alternative protein isoforms little evidence exists for a functional role in
the cell. It therefore seems unlikely that the spectrum of conventional enzymatic
or structural functions is meaningfully extended through these alternative splice
forms.
Introduction
Alternative RNA splicing, the generation of a diverse range of mature RNAs, has
considerable potential to expand the cellular protein repertoire [173, 30, 240, 37,
191] and recent studies have estimated that 40-80% of multi-exon human genes
can produce differently spliced mRNAs [291, 34]. The importance of alternative
splicing in biological processes such as development [287, 292] has long been
recognised and proteins coded by alternatively spliced transcripts have been
implicated in a number of cellular processes, not all of which are advantageous
[85, 263, 234, 280, 183].
The pilot project of the Encyclopaedia of DNA Elements (ENCODE) project
[58], which aims to identify all the functional elements in the human genome, has
undertaken a comprehensive analysis of 44 selected regions that make up 1% of
the human genome. One valuable element of the project has been the detailing
of a reference set of manually annotated splice variants by the GENCODE
consortium [112].
While a full understanding of the functional implications of alternative splicing
is still a long way off, this study is the first assessment of a systematically
collected reference set of splice variants. We have been able to apply the best
and latest computational methods and analysis tools and the most sophisticated
information retrieval strategies to the GENCODE annotations. We are able to
demonstrate that genes with alternative splice forms are in the majority in this
set and that the alternative splice forms annotated here are likely to be an
underestimation of the total pool of splice variants. A high proportion of the
proteins coded for by these splice variants are predicted to be markedly different
in structure and function from their constitutive counterparts.
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Alternative splicing frequency
The annotation by the GENCODE consortium is an experimentally verified
extension of the manually curated annotation by the Havana team at the Sanger
Institute. The project has annotated 2,608 transcripts for 487 distinct loci and
1,097 transcripts from 434 loci are predicted to be protein coding. There are on
average 2.53 protein coding variants per locus; 182 loci have only one variant
while one locus, RP1-309K20.2 (CPNE1) has 17 coding variants (see Figure 1a).
Figure 1. Isoforms per locus. Part (a) shows the number of isoforms per locus
(orange) for the 434 loci in the set compared to the number of protein sequence
distinct isoforms per locus (yellow). Part (b) shows the number of isoforms per
locus in the manually selected regions (red) compared to the number of isoforms
per locus in the regions selected by random stratified procedure (purple). The
manual regions are rich in single isoform loci and this in part can be explained by
the olfactory receptor cluster in manual pick number 9 (supporting online text).
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A total of 57.8% of the loci are predicted to have alternatively spliced transcripts,
although there are differences between those target regions chosen manually and
those chosen according to the stratified random-sampling strategy [58]. The
0.5% of the human genome that was selected for biological interest has 276 loci
and 52.1%of loci have multiple variants. The regions that were selected in the
stratified random-sampling process have less loci (158), but more variants per
locus (2.76) and 68.7% of the loci have multiple variants (see Figure 1b). This
number is towards the higher end of previous estimates, but in line with recent
reports [196].
Much of the difference can be accounted for by the gene clusters in the manually
selected regions for example in manual pick number 9 from chromosome 11 [257]
there are 31 loci that are all labelled with the Gene Ontology [42] term“olfactory
receptor activity”. All 31 transcripts have a single isoform and alone account for
half of the difference between the manual and random set. It is known that these
7 transmembrane helix olfactory receptors are found in large clusters, are recent
in evolutionary origin and their loci rarely have variants. All the variants in this
set have a single large coding exon and thus have more limited possibilities for
alternative splicing.
A large proportion of the data set is composed of splice isoforms with identical
protein sequences. These coding sequence-identical variants are alternatively
spliced only in the 5’ and 3’ untranslated regions and form an interesting sub-
group that may be under independent transcriptional control [298]. One locus,
AF121781.16 (C21Orf13), has 11 alternative isoforms, all of which are sequence
identical. This is not an isolated case: 230 of the 1,097 isoforms are identical,
25 loci have four or more identical isoforms and 15% of the loci with multiple
variants code for nothing but protein sequence identical isoforms (Figure 1).
While there are a large number of identical sequences in the same locus, there are
also identical protein sequences on separate loci, even though the selected regions
only make up 1% of the human genome. Remarkably, protein sequence iden-
tical isoforms of the protein TEX28 HUMAN (Testis-specific protein TEX28)
turn up four times in three different loci. There are two protein sequence iden-
tical isoforms in locus AC092402.6, another in a locus from the same clone
(AC092402.4) and a fourth in a different clone (Z68193.2). All four instances
came from same target region selection - manual pick number 6.
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Gene mapping
Of the 434 genes in the data set, 417 loci have primary gene products that can be
mapped to the Uniprot protein sequence database [288] (Table S1). Structures
have also been resolved for a surprisingly high number of these genes; sequences
from 42 different loci (almost 10%) have at least part of their structure deposited
in the Protein Data Bank [26]. This reflects the effort that has been put into
resolving the structure and function of human proteins. Locus GS1-273L24.4
stands out, it has two sequence-distinct splice variants (MTCP1 and MTCP2)
and the entire structures of both proteins have been solved, in part because of
the gene’s role in T cell leukaemia [51].
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Figure 2. Alternative splicing In part (a) we illustrate some of the potential
types of alternative splicing. A splicing event can be internal as in row I, at the
C-terminal, as in row II or at the N-terminal as in row III. In each case there are
several paths splicing can take around an exon. The usual (constitutive splicing)
path follows the black lines, while alternative splicing can miss out all or part of
an exon, or can substitute on exon for another. Substitution of exons (leading to
substitution of protein sequence) happens most frequently at the terminal ends
of the mRNA sequence as comparisons of the splice isoforms in (b) shows. The
most frequent splicing event is the removal or insertion of a whole exon within
the mRNA sequence.
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Functional and structural characterisation of al-
ternatively spliced isoforms
In this part of the study we concentrated the analysis on the 214 loci that code
for protein sequence distinct splice isoforms. Alternative splicing can take a
number of forms (see Figure 2) and we classified the changes brought about by
splicing events into 6 types. Since deletions and insertions cannot always be
easily distinguished they were pooled. The results agreed with previous studies
[194] - internal changes are almost always deletions or insertions of single or
multiple exons and C-terminal changes tend to be substitutions of one or more
constitutive exons for an alternative exon. Insertions or deletions are rare at
the C-terminal (Figure 2). A number of substitutions in the protein sequence
result from the translation of a different reading frame. For example in locus
RP1-309I22.1 (TIMP3) alternative splicing between exon 4 and 5 leads to a
frame shift in the fifth exon and means that the C-terminals of two variants are
coded for from two different reading frames of the fifth exon. Another example
is RP4-614O4.1 (ITGB4BP, Figure 3). The phenomenon of overlapping reading
frames has been little studied in eukaryotes and there are only three functionally
studied examples in humans. One example is INK4a/ARF21 [215] where dif-
ferent transcripts have CDS sharing 3’ exons in different reading frames. Here
we find that 23 separate loci code for variants with overlapping reading frames.
The examples in this set may not be functional, but the findings suggest that
the frequency of variants with overlapping reading frames might be somewhat
higher than previously suggested [169].
Because of the nature of the manually selected regions, a relatively high propor-
tion of loci code for proteins with trans-membrane helices (TMH). These TMH
proteins are particularly interesting because their genes form clearly defined
clusters, such as the 31 olfactory receptors on chromosome 11 [257], each with
a single exon and no splice variants, and the natural killer cell immunoglobulin
receptors clusters in manual pick number 1.
There are 41 loci that have isoforms with differing numbers of TMH. In most
cases a single helix is lost relative to the principal sequence (the constitutive
splice form), but there are also cases where 4, 5 and even 8 membrane sections
are missing in the isoform. Interestingly, several genes appear to code for both
soluble or transmembrane isoforms.
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Figure 3. eIF6 structure. A structure exists with 75% sequence for the primary
sequence of this locus (eIF6). 1g62A is a complex domain with pseudo five-fold
symmetry and isoform 005 has a central substitution where 85 residues (marked
in purple in the figure) are replaced by 60 non-homologous amino acids. The
missing residues make up two of the five beta-alpha-beta propellers.
For example, locus AC006985.7 (UGT1A10) codes for two isoforms of UDP-
glucuronosyltransferase 1A10. Isoform 002 has a short C-terminal substitution
in place of the C-terminal 89 residue segment that contains a predicted TMH
in the principal sequence, isoform 001. All 64 UDP-glucuronosyltransferases
deposited in the SwissProt database [288] are annotated as monotopic membrane
proteins and no natural soluble form is known. However, an engineered water-
soluble form is reported [159]. If expressed, AC006985.7-002 would be the first
soluble UDP-glucuronosyltransferase naturally encoded.
While splicing events often seem to splice out complete TMHs, there are cases
where it is difficult to predict the resulting membrane topology. In locus AC129929.4
(TSPAN32), for example, the principal sequence (tetraspannin-32) has four
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TMH, but the gene also codes for four different splice isoforms that each lose
one membrane-spanning helix. In isoform 003 the N-terminal helix that acts
as both a signal sequence and a membrane anchor [251] will be affected by an
N-terminal substitution and in isoforms 005 and 012 the C-terminal TMH is
lost, also through substitution. Isoform 014 lacks not just the N-terminal helix,
but also the third TMH. This would leave the isoform as a protein with two
membrane-spanning regions and with the first helix oriented in the opposite di-
rection with respect to the other isoforms! All these cases evidently must force
a change of structure or polarity, and all will result in a change of function if
the protein is stable.
Of the 1097 transcripts, 219 were predicted to have signal peptides, accounting
for 107 of the 434 loci. Unequivocal loss or gain of signal peptides can be seen
in 12 loci. One obvious consequence of this is that localisation will not be con-
served between isoforms. In eight loci the signal peptide loss/gain results from
a substitution of exons at the N-terminus, as seen in RP1-248E1.1 (MOXD1)
where one isoform loses 86 N-terminal residues including the signal peptide.
This is coherent with earlier findings [194] that showed that most signal peptide
gain/loss within alternative splicing products comes about through N-terminal
exon substitution.
In AC010518.2 (LILRA3) signal peptide loss appears to be triggered by an N-
terminal insertion. This results in the apparent internalisation of the signal
peptide. Isoform 003 has a 17 residue N-terminal insertion ahead of the signal
peptide that is predicted for the principal sequence (001). If the signal peptide is
internalised in this isoform, the localisation of the protein will not be conserved.
If this variant turns out to be expressed there is some evidence to suggest that
its expression may be disease-associated the only supporting evidence for this
isoform is in the form of ESTs from leukemia blood.
Definitions of protein functional domains can be extracted from a number of
sources. We used the definitions from the Pfam database [20], both the hand-
curated Pfam-A domains and the automatically generated Pfam-B domains.
The start and end points of Pfam-B domains are less clearly defined, but in-
cluding Pfam-B domains improves the coverage.
Splicing events occur within Pfam-A hand-curated functional domains in 46.5%
of sequence-distinct isoforms and the figure rises to 71% if all Pfam defined
domains are considered. Although this is a surprisingly high figure, it is still
considerably less than might be anticipated. If the same number of splicing
events occurred at random at the same exon boundaries, splicing events would
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be expected to occur inside Pfam-A domains in 59.8% of isoforms (84.8% in
all Pfam-defined domains). It does seem that some form of selection has oc-
curred, either in the generation or conservation of splice variants. As previously
shown [158] this effect is not due to any correlation between domain and exon
boundaries - we found no such correlation (supporting online text).
On occasion, splicing events leave out complete functional domains. In this
set the effect was most marked with the immunoglobulin (ig) domain, a func-
tional domain that is over-represented in the manually-chosen regions. Isoform
007 from locus AC011501.5 (KIR2DL4) is missing the N-terminal immunoglob-
ulin domain and isoform 002 from locus AC010492 loses the second of four
immunoglobulin folds that are present in the principle isoform 001. The iso-
forms in novel protein locus AC009955.5 also consist of strings of ig domains;
one isoform (002) has a C-terminal truncation, whereas (003) has both an N
and C terminal truncation.
The repeated use of splicing in altering immunoglobulin (Ig)-fold copy number
of is particular interest when attempting to understand the involvement of ig-
containing genes in developmental and immune system pathways. While the
numbers of cases is undoubtedly influenced by the significant bias towards ig-
like architecture in the manually-selected regions, it does suggest that this is not
an isolated phenomenon and that it may occur in many other ig-fold containing
proteins. It was also noticeable that no splicing event fell within an ig-domain
in this set.
The infrequent variation in domain architectures that can be observed within
the GENCODE annotations may be biologically meaningful and these loci are
ideal candidates for further deeper study into the potential functionally relevant
effects of alternative splicing.
Although these results do suggest that there is some favourable selection for
splicing events that do not affect functional domains, there are still a large
number of transcripts in this set where a splicing event does occur inside a
domain and that apparently code for proteins with drastically altered structure
and function. For example, in 49 of the 85 cases of alternative splicing where
splicing events occur in regions covered by homologous PDB structures the
resulting protein structure is likely to be substantially altered in relation to that
of the principal sequence.
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From gene expression to translation
Reverse transcription polymerase chain reaction (RT-PCR) experiments can
confirm mRNA expression and it is indeed possible to find data for a marked
number of loci. For example, both variants of AF030876.1 (MEC2P) have been
shown to be expressed [157] and Tsyba et al. [260] confirmed the expression of
a number of variants from locus AP000303.6 (ITSN1).
While it has been possible to confirm the expression of many alternative tran-
scripts, it is important to know whether these genes are actually translated
into proteins and whether the alternative splice isoforms with the most extreme
deletions would become misfolded and quickly removed by the cell degradation
machinery. Also, if the proteins are translated and fold properly, what functional
role might they play in the cell?
It is clear from sequence comparison that a number of loci have alternative
isoforms that must have radically different structures if they are to fold. Isoform
001 from locus RP11-247A12.5 (CRAT) has an 82 residue internal deletion in
its acyltransferase domain (Figure 4) and isoform 005 from locus RP4-61404.1
(ITGB4BP) has an internal substitution that disrupts two blades of the stable
alpha-beta propeller structure (Figure 3). Four separate loci from the serpin B
cluster in random pick 122 have multiple alternative isoforms with large internal
deletions or C-terminal substitutions (Figure 5). In all these cases it can be
shown that the deletions would almost certainly mean that folding and function
are severely affected.
In many of those cases where it was possible to build comparative models for the
alternative isoforms we found that substantial rearrangement would be required
to generate the models (Table S3). These isoforms could not be modelled by
removing, adding or replacing a peripheral part of the protein structure: if these
proteins are to fold properly and not aggregate some alternative structural and
functional explanation must be invoked.
However, there is evidence that at least some alternative transcripts are ex-
pressed as proteins and can fold. Janssens et al. [133] showed that isoforms
008 and 011 of locus RP11-247A12.4 (PPP2R4) are translated in vitro and
even though it is odd to imagine that proteins with radically altered folds are
coded from the same genomic locus, this is exactly what happens in locus GS1-
273L24.4 (MTCP1 and MTCP2). The two isoforms coded from non-overlapping
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regions of this gene have markedly distinct structures: MTCP-1 is a 117 residue
filled beta-barrel, while MTCP-2 is a 68 residue 3-helix bundle (Figure S2).
Experimental evidence for functional differences between splice isoforms is harder
to find. We were able to find just three concrete instances of functional differ-
ences between the splice isoforms in this set. Splice isoform 004 from locus
AC034228.1 (ACSL6) has a sequence similar internal substitution correspond-
ing to exon 11 in the transcript, a substitution that is one of the only two
examples of mutually exclusive exon usage in the entire set. Kinetics assays
show that this isoform has conspicuously different ATP binding affinities [271].
The three experimentally recorded splice variants of locus U52112.3 (IRAK1)
coincide with the three coding sequence identical variants in the GENCODE set.
IRAK1c (isoform 001 in locus U52112.3) has a 79 residue deletion in relation
to the principle sequence (IRAK1, isoform 012) and it has been shown that
IRAK1c differs from IRAK1 in that it does not undergo covalent modifications
such as phosphorylation and ubiquitination upon lipopolysaccharide challenge
and is not translocated to the nucleus [253]. IRAK1c is also the primary form in
human brain tissue. The IRAK family proteins play critical roles in regulating
innate immunity and the authors hypothesise that IRAK1c may keep brain
tissue in a resting non-inflammatory state.
A further locus for which there is evidence of distinct functions is XX-FW83563B9.3
(TAZ). Vaz et al. [273] showed that alternative isoform 002, which has a 31
residue deletion from skipping the fifth exon, may actually be the correct prin-
cipal sequence since it is the only isoform to have full cardiolipin metabolic
activity.
This was not the only locus where doubts have been cast on the biological
importance of the principal isoform. Recent work [224] has suggested that since
cDNAs for many genes were cloned from tumour samples, the prevalent isoform
may well have been coded from a tumour-specific splice variant rather than
the mRNA sequence found in normal tissue. Indeed they found that tumour-
associated splice forms were twice as likely to be represented in GenBank as the
equivalent normal tissue-associated splice forms.
There has been abundant recent work associating alternative splicing with stresses
incurred by cancer and other disorders [165, 152, 204], although rather than
instigating the disease, in many cases the increase in expression of the aber-
rant variant may be a side effect of the general breakdown of cellular function.
However, the importance of alternative splicing in cancer is such that cancer
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diagnosis can now be carried out using isoform-sensitive microarrays based on
splice isoform profiles [38, 297].
It has been shown that at least two sets of alternative isoforms in this set are
implicated in disease states, isoform 011 from locus AC051649.4 (TNNT3) in fa-
cioscapulohumeral muscular dystrophy [128] and isoform 006 of locus U52111.6
(L1CAM) in CRASH syndrome [95]. In addition, the mRNA supporting evi-
dence for a number of variants was found exclusively in cancer cell lines (for ex-
ample isoform 005 in locus Z97634.2, TMEM8, and isoform 003 from AC010518.2,
LILRA3), suggesting that their expression may also be associated with disease
states.
This analysis throws up several key questions, not least of which is whether
the GENCODE-validated transcripts are comprehensive. While the set does
include many known isoforms and uncovers numerous previously unrecognised
variants, it seems very likely that many variants remain to be identified. For
example, only four of the nine experimentally recorded isoforms [152] for locus
XX-FW83563B9.3 (TAZ) are recognised, and the GENCODE set annotates just
3 of 6 Uniprot-recognised isoforms for locus AC011501.5 (KIR2DL4, Figure S6)
and 1 of 4 Uniprot-recognised isoforms for locus AC129929.4 (TSPAN32). In
fact, for the majority of loci that we looked at in detail, there were experimen-
tally recognised variants that were not in GENCODE annotations.
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Figure 4. The potential effect of splicing on protein structure. Four splice isoforms
from the data set mapped onto the nearest structural template. A. Carnitine
O-acetyltransferase isoform 001 from locus RP11-247A12.5 mapped onto PDB
structure 1s5oA. B. Interleukin 4 isoform 002 from locus AC004039.4 mapped
onto PDB structure 2int. C. Hemaglobin delta subunit isoform 002 from lo-
cus AC104389.18 mapped onto PDB structure 1si4D. D. Sorting nexin 3 isoform
003 from locus RP3-429G5.4 mapped onto PDB structure 1ocuB. Structures are
coloured in cream where the sequence of the splice isoform matches the structure,
in purple where the sequence of the splice isoform is missing. The deletions will
mean that the structures of these isoforms would require substantial reorganisa-
tion from the parent structure.
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Figure 5. Clade B serpins. Serpins are primarily irreversible serine protease
inhibitors. Their function is unique among protease inhibitors, they covalently
inactivate their targets after undergoing an irreversible conformational change.
Serpins have a complex fold containing a bundle of 8 or 9 alpha helices and a beta
sandwich with three sheets (shown in silver, yellow and green in the diagram).
They exist in an inactivated form that is regarded as being ”stressed”. Cleavage
at the C-terminal end of the 20 residue RSL region, shown in red in part (a),
allows a large conformation change in which the RSL region flips over and fits
itself into one of the beta sheets. This form is shown in part (b) with the inserted
RSL region in red. This is the form that is able to bind covalently and irreversibly
inactivate the protease. Four serpin loci in the data set have multiple alternative
isoforms with large internal deletions or C-terminal substitutions. In all eight of
the isoforms it appears that the splicing is likely to cause the structure to fold in
a moderately or substantially different fashion. In parts (c) to (f) we show four of
the isoforms mapped onto the structure (1by7A). The sections deleted from the
isoforms are shown in purple. Given that the complex structure of the inhibitor
is vital to its unique function, it is puzzling that many variants exist that code
for proteins apparently deleterious to this functionality.
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Conclusions
We know the effect of splicing on the function for a few of the alternative isoforms
in this set, but even in the cases described above we are still some way short
of knowing their precise role in the cell. Here detailed and technically complex
experimental approaches would be required and for most loci we can do little
more than hypothesise as to the functional importance of splicing.
The study shows that alternative splicing is commonplace and the cross-section
of alternative splicing events apparent at many different loci points to the poten-
tial versatility of alternative splicing in the creation of new functions. However,
while alternative splicing has the potential to be an effective way of increasing
the variety of protein functions, we see very little evidence of an increase in pro-
tein functional repertoire in this data set. In fact alternative splicing can lead
to a wide range of outcomes, many of which may be undesirable. The dramatic
changes in protein structure and function likely to result from the splicing of a
large number of these variants suggest that many are likely to have functions
that are potentially deleterious.
The standard path of protein evolution is usually conceived as stepwise single
base pair mutations. Alternative splicing typically involves large insertions, dele-
tions or substitutions of segments that may or may not correspond to functional
domains, subcellular sorting signals or trans-membrane regions. The deletion
and substitution of multiple exons seen in many of these transcripts suggests
that splicing is not always a mechanism for delicate and subtle changes, but is
a process that is rather more revolution than evolution.
What advantage is there to be gained in the cell from alternative splicing? The
substantial changes evident in many of the alternative splice forms ought to
disrupt their structure and function. Changes of this magnitude would normally
not be tolerated because of the heavy selection pressure that must oppose such
large changes [290].
While there may be as many evolutionary dead ends in alternative splicing
as there are in standard evolutionary paths, one clear difference is that the
organism seems to be able to tolerate these irregularities to some extent. It is
possible that many of these splice variants lie more or less dormant within the
gene and are only highly expressed as a result of some disease event. If splice
variants in low numbers do not adversely affect the organism, the selection
pressure against exon loss or substitution is reduced and the organism is able
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to tolerate the new variants. In this way large evolutionary changes can take
place without significant repercussions, going some way towards explaining why
so many of the alternative transcripts appear to encode proteins that are non-
functional, at least in the classical sense.
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2.3 Distributed systems
Integration implies segregation
As the short introduction to the diversity and abundance of biological data
above shows, a single person or lab usually concentrates on only a few of the
data types involved in sequence analysis. As we enter the post genomic era, the
focus in systems biology is on integrating the diverse and dispersed data to form
coherent pictures. The last sections of this chapter are dedicated to technologies
and efforts to disseminate biological data.
Already when sequence analysis databases were in their infancy, people realised
that at some point they would like to integrate the different data, and that this
would be a tough task. In 1996, Robbins pointed out that the problems with
database interoperability were threefold [222]:
Technical: Technical interoperability must be achieved, so that minimum func-
tional connectivity can be assumed among participating information re-
sources.
Semantic: Semantic interoperability must be developed, so that meaningful
associations can be made between data objects in different databases.
Social: Social interoperability must occur, so that meaningful associations are
made between data objects in different databases.
One could argue that the social component is in fact a integrated problem of
both the technical and semantic problems, as there is no point in developing
syntactic and semantic standards if no one uses them.
Since Robbins’ report, XML and Internet technologies have solved the prob-
lem from the technical perspective, but the much harder problem of defining
semantics for data integration remains largely unsolved. To a large extent, it is
the social factor that is hindering advance, as a plethora of standards for data
definition and sharing has been proposed (see 2.3.2). The problem lies in the
lack of public acceptance of one standard above others, and now that so many
data formats have seen the light of day, the real problem may in fact be how to
map similar objects between data formats [248, 239].
36
2.3. Distributed systems
The importance of being on-line
In 1980, the world of sequence analysis became a bit smaller when Dayhoff
et al. published a sequence database, freely available to all over the telephone
line [60]. Today, few scientists - especially within informatics - can imagine their
jobs or even lives without an Internet connection. I have heard horror stories
that the first biological sequences were published in paper format, and as I sit
here and write this, I can see stacks of CDs reaching towards the ceiling in the
neighboring office, CDs that contain sequence data, dating from times when
download time and -cost for a GB of data were greater than good old fashioned
snail mail. Today, access to the latest data and on-line methods is critical for
success within the field of bioinformatics.
Federation vs. warehousing
Current sequence and annotation databases have a rapid turnover rate, and
bioinformatics labs need to keep their data up to date to stay competitive.
Database integration over the Internet can be achieved in many ways. Dis-
tributed or federated databases are those where the data sources are dispersed,
but the data structure is unified to a degree. There are various degrees of inter-
operability for such databases ranging from total transparency, where the data
sources are geographically dispersed, but the interface is the same, to interop-
erable databases where there is a similarity in data objects, but the interface
is different. Integration of such data sources may be very easy, or very hard,
depending on the level of coordination and standards their design implements.
Making use of federated databases has the advantage that you are guaranteed
to be using the most recent version of their data. The downside is that on-line
sources occasionally go off-line, and having a single data source off-line may
disrupt the projects and applications relying on them totally. An example ap-
plication, relying on distributed databases for data is the CBS DAS browser
described in section 2.4.
Many large projects, which rely on distributed source data, do not rely on
federated access to those data, but assemble their own custom-made databases,
integrating data from various sources. This approach is called data warehousing.
As web-based (bioinformatics) resources are brittle in their nature, warehousing
has been the mode of operation for many large scale integration projects destined
for publication. An example of such an approach is the Inweb created at CBS
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for integration of protein protein interaction data (see section 4.3). The pros
of having such a warehouse are that once implemented, having a local copy of
all the data needed increases efficiency and ease of data manipulation. In other
words: warehouses are self-contained. The cons are that a lot of work and logic
is needed in the design phase to mold the various data sources into a coherent
database. Such data repositories may also contain data sources that are not up
to date and require more control over data versions.
As biological data exchange standards are maturing, some projects are combin-
ing federation and warehousing to create both a stable and up to date resource.
Among those are the Ensembl and UCSC genome browsers [29, 118], which
warehouse genome sequence data, along with annotations from various sources.
Users can then add their own on-line data sources to be integrated to the browser
view.
The greatest difference between these approaches is the robustness vs. con-
currency. When you warehouse data - if you manage to get them into the
warehouse - they remain there in a format of your choice and are easily and
quickly available. Federation on the other hand requires that the data sources
are available all the time as your integrated view of them will be compromised
if and when they go oﬄine. Federation gives you access to the latest data avail-
able at any time, whereas warehouses of data are usually compiled at intervals
and may therefore contain obsolete data. Warehousing demands extra storage
compared to federation. Federation, however, requires more calculations and
network bandwidth at query time.
2.3.1 Identification, versioning and validation
Keeping your data up to date and knowing it is a complicated task. Sequence
and annotation databases have a high turnover rate, constant updating and
error checking is needed.
Accurate integration of bioinformatics data demands that we can verify that
the data and annotations that we collect from distributed sources apply to the
same sequences. This is not a trivial task; many projects and databases use dif-
ferent naming schemes and conventions. There is usually a handful of names for
each sequence. To complicate matters even more, the same genes and proteins
often have different names within the same database. The database entries get
updated and many entry names have more than one version of a sequence tied
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Figure 2.3: The turnover rate of UniProt. Both the automatically annotated
TREMBL and the manually curated Swiss-Prot undergo rapid changes. A protein
entry in either database is likely to be modified on average 4-5 times every year.
Annotation updates are much more common than sequence updates though, with
only 1 sequence update in every 20 in Swiss-Prot and 1 in 5 updates being a
sequence update in TREMBL.
to them. As an example, the human insulin receptor, INSR HUMAN (UniProt
ID), has two sequences tied to it; the entry last modified in 2003. Figure 2.3
shows the average number of updates pr. entry in UniProt, with the average
entry being updated about 4-5 times every year.
Additionally, the fact that we are constantly finding that the mapping between
human genes and proteins is more diffuse that we thought: [43], section 2.2 and
that there may be many more products per gene that previously thought.
As bioinformatics tasks become more and more automated, error checking, ver-
sioning and provenance grow more important.
39
Chapter 2. Components
MD5 checksums
For quite some time, people have used data digests, or checksums, to validate
data being sent over a network. When a message is received or a download
is completed, a checksum algorithm is put to work on the data and the results
(usually a fixed length string) compared to the checksum downloaded separately
for validation. This is a common approach to verify large downloads and that
messages have not been tampered with. The MD5 checksum algorithm [221]
takes as input an arbitrarily long message and outputs a 128 bit checksum.
In the case of biological sequences, ranging from a few residues to several thou-
sand base pairs or amino acids in length, a fixed length checksum is a comfort-
able, computationally generated identifier. We have adopted this approach at
CBS, indexing the major sequence databases with MD5 checksums. We store
the external database identifiers in a synonym table to map from database iden-
tifiers to checksums and from there to the sequence. A very similar approach is
described in [242]. The checksum approach has the advantage over other types
of identifiers that it can be computed from the primary sequence and there-
fore no registry or sequence version information is needed; provided that the
checksum algorithm used has a reasonably large and uniform output space, the
checksums are unique and any two sequences will have the same checksum if
and only if the sequences are really one and the same.
Life Science IDentifiers: LSIDs
The lack of standardization in naming convention within biology has sparked
many projects, one of the most promising being the life science identifiers
(LSIDs) project [53]. The aim of that project is to uniquely identify all entities,
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objects and services within life sciences with URIs4. LSIDs may well become
the standard in biological entity identification as many projects and data repos-
itories within bioinformatics already support LSIDs or have declared they will
in the future: GenBank, PDB, Swiss-PROT, PubMed, DAS, BioMOBY, Gene
Ontology, LocusLink, and Ensembl. As informatics moves toward Internet tech-
nologies and www standards, the use of URIs as identifiers will also become more
and more accepted, within biology and other fields.
2.3.2 Exchange standards
On September 23rd 1999, a NASA spacecraft, the Mars Orbiter, fired its rockets
for the last time before its planned landing on the surface of the red planet. To
the mission control team’s horror, the signal to the $125 million craft was lost
and it presumably crashed into Mars. A subsequent investigation quickly found
the cause of the failure; a simple error in the conversion from English standard
units to metric ones.
While most of the time, errors in conversion between data formats and units do
not result in multi-million dollar loss, more mundane examples of difficulties in
data hacking see the light of day every day. During the writing of this thesis, I
was asked to glue together two protein datasets, interaction data in one file and
sequence similarity scores in another. I spent a whole day trying to understand
why none of the data points were being linked as I tried to match the two.
I finally realised that one of the datasets included a carriage-return (<CR>)
4“URIs or Uniform Resource Identifiers are classified as a locator or a name or both. A
Uniform Resource Locator (URL) is a URI that, in addition to identifying a resource, provides
means of acting upon or obtaining a representation of the resource by describing its primary
access mechanism or network ”location”. For example, the URL http://www.wikipedia.org/
is a URI that identifies a resource (Wikipedia’s home page) and implies that a representation
of that resource (such as the home page’s current HTML code, as encoded characters) is
obtainable via HTTP from a network host named www.wikipedia.org. A Uniform Resource
Name (URN) is a URI that identifies a resource by name in a particular namespace. A URN
can be used to talk about a resource without implying its location or how to dereference it.
For example, the URN urn:ISBN 0-395-36341-1 is a URI that, like an International Standard
Book Number (ISBN), allows one to talk about a book, but doesn’t suggest where and how
to obtain an actual copy of it.” From [284].
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character 5 at the end of each data point and therefore my system did not
match them as equal, even if they looked identical to the naked eye. This was
not my first encounter with <CR> and probably not the last. Had the files
been in a standardised format, this problem would have been avoided and my
head would sport fewer gray hairs.
Due to the fact that standards need to be implemented on various levels, that
is: technical, semantic, and social levels, they take time to be absorbed by the
community. The best way to get a new standard out in the community is to keep
it simple, allowing the community to start using it. The users will then shape
the evolution of the standard, its success or failure. In this way, many practical
solutions are compromises between ease of implementation and elaborate design;
many ingenious data formats never catch on among the target users because of
implementation problems. Given the dynamic nature of biological data (NCBI
usually alters its on-line BLAST text output a few times a year), one might
think that biological standards are a lost cause altogether. The trick seems to
be to have standards as flexible as the data they describe, as oxymoronic as that
may sound.
Microarray data represents complex analysis results, and as with all high-throughput
experiments, the more data points you can integrate, the stronger your statistical
evidence will be. In 2001, Brazma et al. proposed a data format for storage and
exchange of microarray data [36] and now, five years later, this standard, Min-
imal Information About a Microarray Experiment (MIAME), is in widespread
use, paving the way for research integrating microarray experiments from several
labs using different hardware, experimental designs and interpretation methods
[177]. Effective standards for biological data do exist.
As the web has evolved, we now have a plethora of standards to solve the
technical issues of data integration in biology: DAS, Pedro, PSI-MI, mz-XML,
AGML, SBML, SRS etcetera, etcetera. While many data formats are well de-
signed and have shown potential, social factors have hindered their use in the
general community. As examples, SRS [86] was a heavily used format for ware-
housing, implemented at EMBL among others. However, as the format and
tools were commercial products, subject to licensing, the general public never
5“Carriage-return” is an end-of-line character, just like “line-feed” and “newline”. Dif-
ferent computer systems interpret these end-of-line characters differently and while a Unix
system, such as the one I work with most of the time, can see and understand a “carriage-
return” character, it does not display it in any way, so a the strings “INSR HUMAN” and
“INSR HUMAN<CR>” seem identical to a person working on a UNIX prompt, but the two
are not equal, despite looking exactly the same, and therefore are not matched when compared.
42
2.3. Distributed systems
embraced those tools. Likewise, the ASN.1 format6 has proven useful in the
human genome project, and is the primary storage and retrieval format in use
at the National Center for Biotechnology Information (NCBI). ASN.1 failed to
reach scientists in general, presumably because it uses binary encoding, which
makes it hard to read message traffic without sophisticated tools.
PSI to the rescue
In 2002, the Human proteome organization (HUPO) founded the Proteomics
Standards Initiative (PSI) to untangle the mess of data formats and exchange
standards within proteomics [201]. The PSI has since then attacked the stan-
dardization problems in many subfields of proteomics and introduced standards
and guidelines for data for microarray experiments, mass spectrometry, protein
gel experiments and protein protein interactions.
Although the PSI initiative has proven very prolific and technically sound, it
must still be considered immature, and mostly technical problems have been
solved yet, while many problems with the semantics and social factors still
remain. Having such a standard initiative is a big step in the direction of social
acceptance of a standard though.
The PSI molecular interaction format (PSI-MI) [116] is now in widespread use.
The format is very complex and allows for very detailed descriptions of molec-
ular interactions. A huge problem in the initial use cases for the format was
that the different databases providing data in the PSI-MI format, was that the
different providers used format fields for different data types, there was no stan-
dard vocabulary of description, so a custom parser had to be designed for each
data provider, just as if they all had different formats. The standard has now
reached version 2.0, however, and these initial problems are being solved as the
community usage matures and controlled vocabularies to describe fields evolve
[202].
The plethora of standards emerging in bioinformatics reveal the scope of the
problem of biological data integration. While it is obviously better to have well
described standards for data sharing, we now face the problem of having too
6ASN.1 is a popular notation in communications, because of its richness as well as binary
encoding of data which means lower bandwidth and transaction cost of messaging. ASN.1 was
released in 1984, but as the standard has since been upgraded and modified repeatedly, the best
source for information is the ASN.1 web page: http://asn1.elibel.tm.fr/en/introduction/
index.html.
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many such standards to choose from. Lincoln Stein, one of the designers of
the DAS protocol, foresaw this in his 2002 article, “Creating a bioinformatics
nation” [248], where he described the chaos of incompatible data being replaced
or augmented by chaos from incompatible standards. I believe that choosing a
“standard” standard from the soup is just as an important task for the PSI as
defining new ones.
eXtensible Markup Language, XML
XML is a W3C7 recommendation, and as a language a subset of Standard
Generalised Markup Language (SGML), just like HyperText Markup Language
(HTML). It is a language to describe data, but can also include data, and
therefore, XML documents are self-describing and self-contained. It is an ideal
language to describe structured, yet dynamic data and metadata.
The usefulness of XML has shown on the www, where there has been an XML
explosion in the last decade. Virtually all information exchange is now han-
dled with some form of XML formatting, and XML has become the common
denominator of data sharing and processing on the web.
The impact of XML on Internet technologies, has been felt in the discipline of
bioinformatics as most tools in use now offer some sort of XML input/output
handling and virtually all new data formats and standard propositions are coded
using XML syntax.
2.3.3 The Distributed Annotation System
As a partner of the BioSapiens Network of Excellence, 6th. framework EU
project and the Danish Platform for Integrative Biology (DPIB), the Center for
Biological Sequence Analysis has committed itself to disseminate its high-quality
protein annotation methods in a standardised way. The exchange standard
chosen was the popular Distributed Annotation System (DAS) [72]. Section 2.4
gives a thorough description of DAS and related infrastructure at CBS.
7The World Wide Web Consortium (W3C) is an international consortium where member
organizations, a full-time staff and the public work together to develop standards for the World
Wide Web. W3C’s stated mission is ”To lead the World Wide Web to its full potential by
developing protocols and guidelines that ensure long-term growth for the Web.” From [277].
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Having administered DAS sources and programmed DAS software for over 2
years now, I can safely state that, despite its simplicity, DAS is a very useful
standard and will continue to be so as the user community keeps growing. The
CBS DAS browser described in section 2.4 has now been appointed as an offi-
cial BioSapiens DAS browser by the European Bioinformatics Institute (EBI)
and the coordinators of the BioSapiens project. The BioSapiens version of the
browser is available at www.biosapiens.info.
The ENCODE lateral work package to the BioSapiens project has also benefited
greatly from the usefulness of DAS, as most groups within the network were able
to annotate the ENCODE related sequences and distribute their annotations in
a coordinated and coherent manner through DAS in a matter of days.
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2.4 Paper II
Nucleic Acids Research; 33, W468-W470 (2005); doi:10.1093/nar/gki463
Integrating protein annotation
resources through the
Distributed Annotation System
Pa´ll I´so´lfur O´lason
Center for Biological Sequence Analysis BioCentrum-DTU, Building 208, Technical
University of Denmark, DK-2800 Lyngby, Denmark
Abstract
Using the Distributed Annotation System (DAS), we have created a protein an-
notation resource available at our web page: http://www.cbs.dtu.dk, as a part
of the BioSapiens Network of Excellence EU FP6 project. The DAS protocol al-
lows us to gather layers of annotation data for a given sequence and thereby gain
an overview of the sequence’s features. A user-friendly graphical client has also
been developed (http://www.cbs.dtu.dk/cgi-bin/das), which demonstrates
the possibilities of integration of DAS annotation data from multiple sources into
a simple graphical view. The client displays protein feature annotations from
the Center for Biological Sequence Analysis, CBS, as well as from the BioSapi-
ens reference UniProt server (http://www.ebi.ac.uk/das-srv/uniprot/das)
at the European Bioinformatics Institute (EBI). Other DAS data sources for
protein annotation will be added as they become available.
Introduction
In recent years, numerous computational tools for gene and protein analysis
have been constructed by various laboratories. Several such analysis tools have
been created and published by CBS, many of which are available on-line for all
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users at the CBS web page: http://www.cbs.dtu.dk. The analysis results of
such tools has led to an explosion in the amount of data in biological databases
and available information there exists for biological sequences. Today, one of
the major tasks of systems biology is to integrate as much of the experimental
and computational information as possible and thereby gain biological insight
into the properties and function of the macromolecules under observation. This
means the assembly of several types of data, in various formats, dispersed around
the face of the globe into a unified structure. This integration of on-line annota-
tions is greatly simplified if the annotation services follow accepted standards.
One such standard is the Distributed Annotation System (DAS) [72].
DAS services have existed for several years now. Version 1.0 of the DAS spec-
ification was released in 2001 and version 2 is under development. The DAS
protocol is a simple http-based client-server system. A query on the form of
a URL is made to the server, which replies with annotations for the sequence
entry specified in the URL query. The server reply is XML formatted. The
DAS web page (http://www.biodas.org) has both Perl- and Java-based server
software for download. Client libraries in Perl and Java are also available.
The DAS specification was originally written with genomic sequences in mind,
but the standard has proven itself flexible enough to handle protein data as
well. Several annotation databases are now serving annotations using the DAS
system, including Ensembl [124] , FlyBase [73], UniProt [15] and WormBase
[48].
The flexibility and success of the DAS protocol has made it the annotation
method of choice for the BioSapiens Network of Excellence, of which the CBS
DAS server detailed here is a part. The various consortium members will in the
near future deploy several DAS servers, which will serve protein annotations for
the same UniProt sequences as the DAS server at CBS and all the data can
therefore easily be integrated in a coherent manner.
The full list of query types that the DAS specification supports is beyond the
scope of this document, we refer readers to the DAS web page and specification
for detailed information and suffice to say that for queries on protein sequences,
the most important queries are probably ”sequence” to which a reference DAS
server responds with the full sequence and ”features” to which reference and
annotation servers respond with feature annotations they store for a specified
sequence identifier. An example query to the CBS DAS server is shown below.
47
Chapter 2. Components
Server infrastructure
At CBS, we have implemented a Perl-based DAS server, ProServer (http:
//www.sanger.ac.uk/Software/analysis/proserver), which accepts queries
at the address: http://genome.cbs.dtu.dk:9000/das. We serve annotations
for several of CBS’s protein sequence annotation servers, which predict protein
sorting (LipoP [143], NetNES [160], SignalP [24], SecretomeP [23], TargetP [80]),
protein post-translational modification (NetAcet [149], NetPhos [31], NetO-
Glyc [142], NetNGlyc, ProP [74]) and protein structure and function (TMHMM
[244]). Statistics and data source names for the individual methods are shown
in table 2.1. The annotations served by the DAS server include: The start and
end position of the feature annotated; the score from the prediction method that
assigned the feature; a hyperlink to the web page of the prediction method with
sequence information preloaded in the form input and possibly some further
information.
In general, the annotations span all of UniProt [15], but are limited to phyloge-
netic subsets of the database, as the annotation methods are usually constructed
with a specific phylogenetic group as a target (see the reference for each server
for details). At the time of writing, the CBS DAS servers provide over 18 mil-
lion protein annotations for over 1.5 million protein sequences from the UniProt
database and we hope that this wide coverage makes our services of general
interest to the scientific community. The predicted annotations include several
highly cited methods e.g. SignalP and NetPhos, which are among the top 1%
of the most cited papers in the scientific literature according to the Institute for
Scientific Information, ISI.
The annotations are precalculated and the results stored in a relational database,
allowing for fast retrieval and update of data.
Regarding the terminology of the predicted features, we have mostly used the
nomenclature of the original prediction method. In some cases, we have mod-
ified the feature names to mimic the UniProt feature table, thus reflecting the
reference database structure, allowing for easy comparison between the reference
UniProt server and other annotation resources. It is quite conceivable that the
vocabulary will be updated at a later point to make use of standard ontologies
such as the Gene Ontology (GO) [10], so that post-translational modifications
would be mapped onto GO “biological process” etc. The concept of the Se-
quence Ontology (SO) (http://song.sourceforge.net/) is highly relevant to
this project, however the SO does not yet provide sufficient coverage of protein
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Method Data source name Organism coverage Number of records Reference
LipoP-1.0 lipop Gneg 7,597 [143]
NetAcet-1.0 netacet E 122,664 [160]
NetNES-1.1 netnes E 1,945,054 [149]
NetNGlyc-1.0 netnglyc H 137,800
NetOGlyc-3.1 netoglyc M 81,310 [142]
NetPhos-2.0 netphos E 8,940,654 [31]
ProP-1.0 prop E 127,553 [74]
SecretomeP-1.0 secretomep E 58,318 [23]
SignalP-3.0 signalp E, Gpos, Gneg 1,189,706 [24]
TargetP-1.01 targetp E 750,111 [80]
TMHMM-2.0 tmhmm A 5,086,476 [244]
All above combined cbs total 18,447,243
Table 2.1: Annotation methods provided by the CBS DAS system. The annota-
tion methods are specific to the following phylogenetic groups: ”A” stands for all
proteins, ”E” for eukaryotes, ”Gpos” for gram positive bacteria, ”Gneg” for gram
negative bacteria, ”H” for human and ”M” for mammals. The data source name
is the name of the particular annotation method on the DAS server.
sequence attributes, such as post-translational modification, to be useful for our
purposes.
A query example
When querying a DAS server for annotation, one must append the data source
name (DSN), along with a query type and a sequence identifier to the address
of the server. For example: If we wish to ask for annotations from the SignalP
signal peptide prediction method [24] for the protein EGFR HUMAN we first
append the DSN for that method (“signalp”, see table 2.1). Then we use the
”features” query to ask for feature annotations and identify the sequence as a
”segment”. The whole query string thus looks like this: http://genome.cbs.
dtu.dk:9000/das/signalp/features?segment=EGFR_HUMAN.
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Figure 2.4: The CBS protein DAS viewer. The browser interface is very simple,
it has only one form field and the graphical tracks show the annotations for a
given UniProt protein. Additional information for individual features is shown
in a pop up help window when the mouse is pointed at the feature.
CBS DAS viewer
As the raw XML output of DAS servers is not very suitable for browsing of
feature annotations, we have developed a client viewer to allow visualization of
CBS DAS annotations in a simple graphical way. This viewer is publicly avail-
able at http://www.cbs.dtu.dk/cgi-bin/das. All the user is required to do
is to input a UniProt accession number or identifier. The viewer then collects
the annotations served by the CBS DAS servers, along with annotations from
a UniProt reference DAS server at the EBI (http://www.ebi.ac.uk/das-srv/
uniprot/das) for that particular sequence. All the annotations are then dis-
played as aligned graphical tracks, allowing for easy inspection of features along
the length of the protein. Additional information about the annotations is shown
in a pop-up window when the user points the mouse to an annotation track.
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This is the first time CBS provides a composite graphical display of several
of its protein prediction methods simultaneously, which the users of CBS pre-
diction services may find interesting. Some types of feature annotations carry
a hyperlink in the XML payload. When the user clicks on a graphical track
for such an annotation, the CBS DAS protein viewer will open a new browser
window, following the hyperlink. The graphical tracks can also be folded and
expanded to allow simplified overview. A screenshot of the client in action can
be seen in figure 2.4. The client demonstrates how easily different data sources
can be integrated using the DAS system. We plan to incorporate relevant DAS
protein annotation resources into the graphical client as they appear. At the
time of writing, only one external DAS source is incorporated in the view; a re-
source where RCSB Protein Data Bank [68] structures are aligned upon UniProt
entries, provided by the Sanger Institute (http://www.sanger.ac.uk).
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2.5 Web services and workflows on the net
2.5.1 The semantic web
In an article in Scientific American from 2001, the inventor of the world wide
web, Tim Berners-Lee8 , produces an imaginary scene where two people schedule
a series of meetings, book a venue and rearrange less important coinciding tasks
automatically with the use of web agents9 .
It may be hard for people to imagine that the chaotic mess that is the Internet
will acquire such logic and functionality in the near future. But who, only
ten years ago, could have predicted the impact that mobile phones, handheld
wireless devices, and last - but not least, the world wide web would have on our
everyday lives.
Berners-Lee’s vision of a semantic web really isn’t far-fetched; what seems to be
artificial intelligence in agent software, making arrangements for users on-line, is
really simplified with syntax standards and formal descriptions of services that
are already available on the web. The whole point of the semantic web is to
automate tasks; to use registries to discover distributed services, ontologies to
determine the nature of these services and the entities and objects used.
Using protocols such as web services description language (WSDL), simple ob-
ject access protocol (SOAP) and resource description framework (RDF)10 , along
with dozens of other web object description standards, on-line analysis services
can be described in a machine-understandable fashion and then there is little
logic needed to connect the dots and create smart workflows such as ordering
lowest-possible airline fares, making an appointment at your dentist, and writing
up a list of groceries that your Internet-connected refrigerator is running low on.
All the case scenarios described here above are already existing technologies, not
sci-fi fantasies. The technology is available. The greatest problems are, how-
ever, to find the relevant services and to decide whether to trust them or not.
The trust issue is related to Internet security, and I will not discuss that field in
8Berners-Lee invented the web as a means for scientists to easily share papers and docu-
ments on-line, while working at the European Organization for Nuclear Research (CERN).
9Agent: A piece of software that runs without direct human control or constant supervision
to accomplish goals provided by a user. Agents typically collect, filter and process information
found on the web, sometimes with the help of other agents. From [27].
10RDF and SOAP are W3C recommendations, WSDL is expected to become a W3C rec-
ommendation as it matures.
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here. The problem of finding relevant services for the workflow or arrangements
you wish to perform on-line has been discussed for some time in the literature,
and while there are protocols for finding relevant web services (e.g. universal
description, discovery and integration, (UDDI), protocol [265]) and some have
suggested to simply crawl all of the web for them [94], using “knowbots”. At
the moment, the practical solution is to use a registry of available services along
with a description of their methods, input and output objects as suggested by
Lincoln Stein in [248]. Indeed, my own experience from the DAS work in the
BioSapiens network is that a registry is an easy-to-use, practical, and, if stan-
dardised, easily automated way of keeping track of relevant data and analysis
methods on the web.
The requirement of being able to access analysis services on-line is felt at CBS,
which is a part of several projects, that require on-the-fly computations and
access to databases. In anticipation of these requirements, we have set up web
services for most of the protein annotation servers available at the CBS analysis
site (http://www.cbs.dtu.dk/services). While these services are strictly a
pilot test, they were successfully set up and are currently being used by some of
our partners. Figure 2.5 shows how client software can access CBS’ web services
and run distributed workflows with sequence analysis performed in real time.
Ontologies
In an attempt to glue data and standards together, several efforts have been
initiated to decide on a controlled vocabulary to describe the objects and entities
allowed in biological data formats. Gene Ontology (GO) [111] is the best-known
of these and the model for most new biomedical ontology projects. While GO
is in many ways useful in describing data, its dynamic nature and constant
development make it a difficult platform to use for automated tasks as it is of
course hard to use a standard, if the standard is in constant flux.
Many new projects have followed the GO and as with syntax standards, now
it seems as if the future challenge will not be to use a controlled vocabulary,
but to select a single one and implement as the controlled vocabulary. Open
biomedical ontologies (OBO) [197] is a consortium of ontology projects, ranging
from genomics to phylogenetics to phenotypes. The OBO aims at standardis-
ation of its member vocabularies and, as such, has the potential to become an
ontology of ontologies; a registry where researchers working with data integra-
tion can fetch controlled vocabularies, not just for a data set from one domain,
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Figure 2.5: CLC Bio’s workbench, a tool to integrate sequence annotations from
distributed web services. Here shown with two of CBS’ web services loaded,
SignalP [24] and TMHMM [244], performing computational sequence analysis on
the fly.
but for all domains of their research data. The ontology lookup service [59] is
an interface to search ontologies that conform to the OBO standard.
Automated tasks
Today, workflow design in bioinformatics has reached so much maturity that one
can call a registry, find an appropriate service, based on input and output, and
assemble a workflow for your data. Several projects have been initiated to aid
the construction of such pipelined workflows in biology: BioMOBY [285] and
myGrid [250] focus on the networking and workflow enactment, while graphical
clients such as Taverna [125], BlueJay [261], biowep (http://bioinformatics.
istge.it/biowep/index.html), REMORA [44], and others allow users to cre-
ate custom workflows and run them.
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The building blocks are there and once the user interfaces for these services
become more robust and intuitive this type of automation is sure to become
widespread.
2.6 Where to?
Biological sequence data is being produced at ever-increasing rates and there is
constant need to counter the growth with faster computers and more efficient
algorithms for analysis. The problem of data diversity is more difficult to solve.
In this chapter I have (I hope) produced a picture of the growing amounts and
diversity of biological data. The trend in bioinformatics is towards a systems
view of the cell; a bird’s eye view that demands integration of all possible (and
impossible) data types and even untyped data such as free text, that pertain
to the components of these systems. As data integration implies that we have
disparate data sources, this chapter has also described data distribution systems
for biological information and my work in that field.
The informatics community has realised that something needs to be done to
make sense of all the information and there are countless efforts towards data
formats, information sharing standards and even an improved world wide web.
The future challenge will be to pick one standard above others, or even adding
a new layer of abstraction and start defining standards for standards.
As with other informatics disciplines, bioinformatics is riding the wave of In-
ternet technologies, providing on-line access to methods and data. The world
wide web is becoming more than just a storage of documents. It is becoming
an on-line lab, enabling scientists to run analyses directly on their screen. The
use of the web as a tool, rather than just static data, requires that we think of
information on the web in a new way.
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Most proteins do not perform their function alone, but in concert with other
proteins, whether as part of the same obligate complex or during a transient
chemical reaction. Knowledge of protein-protein interactions will undoubtedly
answer many of our questions regarding the function and properties of the in-
teracting proteins. Several methods have been devised in the past few years
to predict protein-protein interactions, with a varying degree of success. The
high false positive rate of available experimental data, the lack of decidedly
non-interacting protein pairs for use as negative data and lack of understanding
of the true driving force behind protein-protein interactions, make the body of
work published so far hard to assay and benchmark. In this work, we point out
possible pitfalls in the handling of protein-protein interaction data with the aim
of creating a prediction method.
Having introduced the components of genes and proteins and the annotations
tagged onto them by distributed analysis services around the globe, it is now
time to start connecting the dots. To gain a bird’s eye view of the systems that
the components are a part of; to analyse the whole instead of the individual,
we need to start making links. The links can be based on the annotations
introduced in chapter 2 or some other type of evidence.
Our ultimate goal is a systems’ view of the cell’s proteome. The natural back-
bone of such a system is the interactome, which describes physical interconnec-
tions between the protein components. This chapter describes efforts to produce
such a scaffold. We then proceed to attach annotations onto the interactome
and analyse it as a whole in chapter 4.
3.1 What are protein-protein interactions?
The most direct cellular relationship possible between any two sequences is direct
physical contact. In proteomics, this means protein-protein interactions (PPIs).
There are however several types of PPIs possible; there are transient types
such as enzyme-substrate reactions, obligate complex formations and in between
those types we have dynamic interactions, such as cyclin binding, demonstrated
to be under dynamic control of the cell cycle [61].
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3.1.1 Physical interactions
Physical evidence of protein-protein interactions can be derived in many ways,
with two experiment types being the greatest contributors: yeast two-hybrid
(Y2H) screens and complex purification followed by mass spectrometry (CP).
Protein microarrays are a promising, but immature, addition to the field.
Yeast two-hybrid assays
This experiment type was conceived by Fields and Song [89] and relies upon the
modular nature of transcription factors, i.e. that they are composed of a DNA
binding domain and an activation domain. The two proteins being analysed
for interaction are hybridised, one to the DNA binding domain and the other
to the activation domain. If the two proteins, usually dubbed bait and prey,
interact, the transcription factor becomes functional and a reporter gene gets
transcribed. The yeast two-hybrid (Y2H) procedure is thus performed in vivo
and is the first of two technologies that have been performed to map the physical
interactions of an organism on a large scale [127, 266].
Complex purifications
The second experiment type used to derive physical interactions between pro-
teins on a large scale is complex purification, followed by mass spectrometry
(CP) [205]. In this approach, bait proteins are tagged with a molecule or chem-
ical, over-expressed in cells, and then protein and its binding partners are puri-
fied. After separation with gel electrophoresis, the proteins are identified with
mass spectrometry. A common way to isolate the bait is to tag the it with an
epitope and use an antibody to precipitate it and its stable binding partners.
This approach can reveal all the constituents of a complex in one experiment,
but it is hard to say which of the complex proteins actually interact physically
(see section 3.1.3 below).
Protein chips
Protein chips, or protein microarrays, [174] promise to enable high-throughput
analysis of protein binding. The concept is similar to DNA/RNA microarrays,
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where the sequence is spatially fixed on a plate surface and binding partners
are applied in solution. Protein array technology, however, is still immature as
proteins are much more variable in chemistry and 3-dimensional structure than
nucleotide sequences, making it hard to reproduce the true character of proteins
as a spot on an array [156].
3.1.2 Implicit interactions
Biological experiments often imply interactions between genes and proteins de-
spite there is no direct physical evidence for those reactions. Several types of
such knowledge-based evidence have been put forth lately. The next section
will touch upon the most commonly mentioned types of indirect interaction
evidence.
Genetic evidence
With the ongoing analysis of the vast amount of genomic information available,
several types of empirical data have been shown to be correlated to PPIs. Qin
et al. [214] showed that the evolutionary classification of proteins is correlated
with their tendency to interact, implying an evolutionary synergy among inter-
acting proteins. In a similar vein, several studies have revealed that interacting
protein pairs co-evolve and that the alignment distance matrices calculated for
the proteins can be used as an indicator of their tendency to interact [102, 207].
Further, building on the phylogenetic trees of interacting proteins, correlated
mutations have been used to predict the contact residues of interacting proteins
[208]. Two studies have revealed that gene fusion events in one organism in-
dicate that the two constituent proteins interact in other organisms [176, 81].
Direct, physical evidence for PPIs has also been mapped between organisms us-
ing sequence homology between the interacting protein pair and a similar pair in
a different organism. Such interacting homologs are dubbed interologs [88, 146].
The STRING database [186] integrates many such knowledge-based associa-
tions into a unique, benchmarked score for each proposed interaction, as does
the approach by Lee et al. [166]. Valencia and Pazos have written an excellent
review of such knowledge-based methods: [267].
60
3.1. What are protein-protein interactions?
Co-expression
Co-expressed proteins also show a higher tendency to interact than proteins that
are not co-expressed. This is true especially in the case of permanent complexes
such as the ribosome and proteasome [130, 131]. Studying the dynamics of
complex formation, de Lichtenberg et al. postulate that in many cases, the
expression of single proteins controls the assembly of a whole complex [61].
Pathway co-occurrence
Proteins that take part in the same pathway in the cell are often annotated
as interacting. Thus von Mering et al. use co-occurrence of proteins in KEGG
pathways as benchmarks and validation of protein associations in the STRING
database [186].
3.1.3 Public data
The abundance and usage of protein-protein interaction (PPI) data has exploded
in the field of bioinformatics recently. The two largest sources of PPI data,
the Y2H screens and CP experiments, have produced thousands of links in
proteomics research.
As a model organism, the budding yeast S. cerevisiae is, by far, the best covered
organism, both with regard to proteome coverage as well as absolute numbers
of published interactions [266, 127, 97].
While PPI data holds much promise for functional genomics and systems bi-
ology, this data source has shown itself very biased and error-prone [276, 14].
Therefore, there is as much, or more, work published that focuses on clean-
ing and benchmarking such data, as there is work that makes use of them in
integrated research.
Reliability of PPI data
As stated above, there are mainly two sources of experimental PPI data; the
yeast two hybrid assay [89] and complex purification and identification by mass
spectrometry [205]. A large concern is the lack of overlap between Y2H and
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CP data. Several studies have shown that the overlap in the accumulated in-
teraction data in yeast is less than 5% [14, 276]. This discrepancy may indicate
that the two experiment types capture different types of interactions, where
CP mainly produces stable complexes and Y2H yields more transient, binary
interactions [134, 98, 5, 147]. Indeed, Edwards et al. found that Y2H assays
did not report any of interactions between proteins in the proteasome [77], and
conversely, several kinase-substrate reactions were identified in high-throughput
Y2H studies [266, 127], but not found in the large-scale complex purification
studies of Gavin et al. [98] and Ho et al. [119].
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Figure 3.1: Spoke and matrix models of CP experiments. This diagram depicts a
fictional complex, where proteins are physically connected as the leftmost figure
shows. In the spoke model (middle) interactions are derived between the bait
(red) and all prey proteins (blue). In the matrix model, interactions are inferred
between all proteins, regardless of them being baits or preys. For the complex
in the diagram the spoke model has 4 correct PPIs, one false positive PPI and
is missing two PPIs. The matrix model captures all the PPIs, but at the cost of
adding nine false positive PPIs.
When analysing CP data for complex pulldowns, it is hard to figure out which
of the proteins, that are co-purified, actually interact physically. Two models
are used to infer the interactions from a complex [12]: the spoke and matrix
models.
The matrix model: A physical interaction is assumed between all pairs of
co-purified proteins.
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The spoke model: A physical interaction is inferred between the bait protein
and all the prey proteins, but not between pairs of prey proteins.
Neither PPI derivation is perfect, but rather a compromise and one must choose
accordingly. Do you want to exclude as many false positives as possible or do
you want to maximise data yield, at the cost of false positives?
The numbers of derived interactions from spoke and matrix data are n− 1 and
n2−n
2 , respectively, where n is the total number of proteins purified.
It has been argued that the spoke model depicts the pairwise physical interac-
tions in a complex three times more accurately [12], but generally speaking it
is hard to assign correct pairwise interactions based on CP data, as the prey
proteins may just as well be attached to one another as to the bait protein. If
one hypothetically uses all proteins found in a complex as baits, one at a time,
it seems logical, that it will generally be the same proteins that are pulled down
each time and therefore the matrix model can be viewed as an extrapolation of
the spoke model for hypothetical assays of complex pulldowns over all proteins
found in a complex. In addition, the spoke model only has 2/n times the in-
teractions of the matrix model, where n is the total number of proteins in the
experiment, bait and preys, so the data loss from matrix to spoke is considerable.
There is a flip side to that data loss, as the amount of pairwise PPIs derived by
the matrix interpretation grows as the square of the number of proteins purified.
This results in a combinatorial explosion for large complexes. As an example,
the MIPS database identifies almost 140 proteins as taking part in ribosome
formation. If a pairwise interaction is assumed between all those proteins, the
resulting number of derived ribosomal PPIs is 140×1392 = 9730. In this way
the number of ribosomal interactions would amount to a large percentage of
the total interactome. I will return to this discussion when discussing data
preparation and potential pitfalls of PPI prediction later in this chapter.
Databases
A number of databases designed to store and serve PPI data have been pub-
lished. The European collaboration database, Intact [117], has grown to be the
largest PPI database publicly available. The Intact effort warehouses data from
the other databases, and usually there is considerable overlap in the data stored
in the databases. Two highly cited efforts are DIP [230] and BIND [100], which
have stagnated a bit in the last couple of years. A novel resource is the HPRD
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Figure 3.2: Major PPI databases and their growth rate measured in the number
of PPI pairs contained. (Statistics and figure by Olga Rigina, olga@cbs.dtu.dk.)
database [190], which is by far the largest source of human PPI data, as it is de-
rived by manual curation efforts. All these huge PPI resources and many more
have been warehoused at CBS for some years now, allowing for the integration
and analysis of a huge body of PPI data, paving the way for direct PPI research
as described in this chapter and for indirect usage of PPI data in projects such
as disease gene candidate prioritisation (see chapter 4).
Journal text
As described in the previous chapter, the volume of published articles is rocket-
ing and researchers have a hard time to follow the body of current research, even
in a narrow field. Several groups have initiated text mining efforts to extract
functional relationships between protein pairs. While such relationship data is
noisy and often the nature of the interactions fuzzy, it is clear that research in
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this greatest resource of scientific data is important. See [186, 120, 295] to name
a few approaches.
3.2 Prediction of protein-protein interactions
While protein-protein interconnection data have already proved important for
systems biology, two great problems accompany these data, namely that cov-
erage for H. sapiens is low, and that the experimental data are full of noise
[276, 14]. Therefore we wish to construct methods to computationally validate
experimental PPI data, as well as predict novel interactions. With this objec-
tive, we look at individual protein pairs, at their chemical properties, predicted
functionality and domains. In chapter 4 we look at the network as a whole, and
validate individual links based on the network neighborhood and topology.
In addition to the genetic/knowledge-based methods described above, there have
been numerous efforts made to predict PPIs from primary protein sequence.
This section is concerned with PPI prediction from sequence and sequence-
derived features using machine learning and statistical methods.
Since its birth in 1993, the Center for Biological Sequence Analysis has had a
strong profile in sequence annotation derived by machine learning and predic-
tion. Prediction methods such as SignalP [24], and NetStart [209], to name two
popular servers, can produce results on novel data in negligible time and there-
fore guide experimental work , thus saving time and labor. For the duration of
my Ph.D. work at CBS I have striven to construct a prediction method that,
for a given pair of protein sequences, can produce a qualified prediction whether
they interact or not. This project turned out to be a much more difficult task
than expected, as far as data preparation was concerned, mostly because the
data are different than those generally used in sequence analysis in that a pair of
sequences is under observation at a time. This fact renders many conventional
approaches to sequence encoding and redundancy reduction useless.
In addition to describing our work, the following sections give an introduction
to the machine learning algorithms employed in our work and highlight some of
the difficulties involved in the prediction of PPIs.
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3.2.1 Machine learning
Several types of machine learning methods have been employed to predict PPIs.
Here I will briefly describe two machine learning techniques, commonly used for
sequence-based purposes at CBS.
Artificial neural networks
Modeled after the nervous systems, artificial neural networks (ANNs) are com-
plex structures of simple units called neurons, each having input and output
signals. ANNs exist in a number of architectures and employ several different
learning algorithms. They have been successful in many fields, including speech
recognition, credit card fraud detection and model airplane auto-piloting. They
are known for their general learning ability and robustness to noisy data.
Just like real neurons, the artificial neurons receive a number of input signals,
each carrying an individual weight, a non-linear function, commonly a sigmoid,
is applied to the weighted sum of inputs. If the result exceeds a predetermined
threshold, an output signal is triggered; the neuron “fires”.
Figure 3.3: A simple diagram of a 3-layered artificial neural network. The input
layer scans and applies weights to the input vector. The hidden layer adds weights
to the output from the first layer and finally, the output layer aggregates the
signals from the previous layer and, depending on the aggregate and the firing
threshold, either fires or not to make its binary classification.
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Figure 3.4: The kernel trick. Support vector machines map data to a higher
dimension, where they are better separable by a plane.
These simple neurons are then arranged in complex, highly interconnected net-
works. The broad range of network architectures that has been described in
the literature is beyond the scope of this thesis, readers are referred to [16] and
references therein for a more general background of ANNs.
For the remainder of this short ANN introduction, we will focus on the network
architecture employed in our work on PPI prediction.
We used a feed-forward type network, where the flow of information is unidirec-
tional from the input layer, which in our case is where the sequence or sequence
features are represented by vectors, to the output layer, where a classification
is made by examining the values that the output classification neurons achieve.
The PPI classification problem is binary: the pair of proteins under investiga-
tion either interacts or not, so there is only need for two output neurons, one for
each case. Generally in an N-ary classifier, there is need for N output neurons.
The goal of the neural network is of course learning, which is obtained by train-
ing. This is in practice done by exposing the network to known classification
examples, continuously updating the weights so that the output values match
the known class. Our networks use the back-propagation [16] algorithm to up-
date the weights.
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Support vector machines
Support vector machines (SVMs) are a relative newcomer to the field of ma-
chine learning and classification. Although Vapnik described the basic idea of
a hyperplane separation algorithm back in 1963, it was not until 1995 that
such classifiers became practical and the name support vector machines was
coined [272]. Since then, SVM applications have grown explosively in number
and proved equal to or better than many other learning strategies in various
classification tasks.
The basic idea behind SVMs is to map feature vectors from different classes to
another “space” where vectors of different classes can be separated by a hyper-
plane. The mapping between spaces is performed by a kernel function, which
can be one of several types. This so-called “kernel trick” allows a classifier to use
linear separation in a higher dimension space to solve a problem, which maps
back to a non-linear separation in the original problem space.
Of particular interest to our application of prediction PPIs are linear, structural
SVMs [138], which can be trained in a much smaller time frame than most other
classifiers and are therefore applicable in situations where the input is a vector
of high dimensionality. Linear SVMs have proved successful in classification
problems with sparse input vectors with several thousand dimensions [138].
Performance assessment
When performing classification and prediction tasks, the outcome is measured
in true and false predictions. There are several composite metrics that make
use of the true and false positives and negatives, the most common ones listed
in table 3.1.
Specificity, or precision, is the ratio of true positive predictions to all positive
predictions, while sensitivity, or recall, is the ratio of true positive predictions
to all positive examples. There is usually a trade off between sensitivity and
specificity for a given prediction method. A commonly used function to optimise
the trade-off is the Matthew’s correlation coefficient [185]. Another is the so-
called receiver-operator characteristics (ROC) curve, which shows the specificity
plotted against sensitivity. The area under the curve is a good measure of the
performance of the classifier and thus a good function to optimise during training
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[299]. For a more theoretic and detailed discussion on performance assessment
in machine learning, readers are referred to [17].
Specificity tp
tp+fp
Sensitivity tp
tp+fn
Accuracy tp+tn
tp+fp+tn+fn
Matthews correlation coefficient (tp×tn)−(fp×fn)√
(tp+fn)×(tp+fp)×(tn+fp)×(tn+fn)
Table 3.1: Some common performance assessment metrics in machine learning.
tp, tn, fp, fn stand for true positives, true negatives, false positives and false neg-
atives, respectively.
Many recently published methods on PPI prediction reach high precision and ac-
curacy, but one must remember that interaction maps are extremely skewed data
with the number of negatives (probably) outweighing the number of positives
by a factor of hundred to thousand. In the case of the model organism budding
yeast, S. cerevisiae, the latest estimate of the number of proteins is about 6000.
Without considering constraining factors such as subcellular localisation, the
possible number of pairwise interactions, including dimers/self-interactions, is
60002/2 = 18, 000, 000. An estimate of the number of interactions in yeast is
about 30,000 [104], so the ratio of interacting to non-interacting pairs is about
1/600 or 0,25%. Knowing this approximate ratio beforehand can lead to a
simple prediction method: namely to predict one of every six hundred pairs
to interact and the remaining 599 ones not to. Such a prediction method will
produce 30,000 positive predictions and 17,970,000 negative ones when applied
to the yeast proteome. By random hits this method will probably produce 50
true positives, 29,950 false positives, 29,950 false negatives and 17,940,050 true
negatives. The number of “true” predictions is therefore 17,940,100, leading to
accuracy of over 99%, which is of course highly misleading for such random
guessing. This demonstrates the need to use unbiased performance metrics to
validate a prediction method. See [17, 16] for more details.
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Specificity 0.0017
Sensitivity 0.0017
Accuracy 0.9967
Matthews correlation coefficient 0
Table 3.2: The performance metrics from table 3.1 when performing a random
guess assignment of protein interactions in yeast. With a skewed data set such as
the interactome, where the ratio of interacting to non-interacting pairs is 1/600,
one has to be careful in choosing meaningful performance metrics.
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Abstract
Protein-protein interaction data describe connections between pro-
teins in the cell, providing clues about their properties and func-
tionality. Experimental interaction data are notoriously error prone
and human data scarce. Therefore many labs have produced meth-
ods of predicting protein protein interactions, attempting to get a
clearer picture of the interactome. Accurate protein-protein interac-
tion predictions allow us to clean up these noisy data sets and provide
interactome coverage for H. sapiens. There are, however, serious ob-
stacles to successful interaction prediction and reasons to doubt that
the task is as straightforward as recent literature indicates.
Introduction
Accurate prediction of protein-protein interactions (PPIs) has a potential to
be a valuable tool for the future development of systems biology and for many
other tasks within bioinformatics in general. Reliable predictions of interaction
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partners for any protein in a given pathway or complex can cut down time
and cost in the laboratory and focus the experimental resources on targeted
cellular studies of interest. Unfortunately, successful PPI prediction is not as
straightforward as recent literature has indicated.
Comparing existing methods for PPI prediction is not trivial, as several types of
data and methods have been utilised for this task. The earliest computational
methods predicted the site of interaction in protein complexes (the “docking
problem”), rather than whether two proteins interact or not. Methods for pre-
dicting the interaction sites in proteins are usually focused on the surface fea-
tures of proteins of known structure [140], or on conserved sequence patterns in
families of interacting proteins [45], or both [87]. Pazos and Valencia suggest
that correlated mutations and the in silico two-hybrid method [206, 208] may be
useful in the latter approach [267]. A review of docking prediction methods can
be found in [241]. CAPRI (A Critical Assessment of PRedicted Interactions)
[129], is a contest, that focuses on prediction of interaction sites of proteins to
aid structural modeling.
With the emergence of high-throughput PPI detection methods [89, 119, 300],
the interactome knowledge coverage has been vastly improved, even though
the currently available data seem to suffer from low accuracy [276]. These large
amounts of data allow for implementing machine learning methods in the field of
predicting PPIs. Since the publication of high-throughput PPI data sets, several
machine learning methods have been developed. Bock and Gough developed a
data-driven prediction method, using calculated property vectors and support
vector machines (SVMs) [32]. Martin et al. approached the problem in a similar
way, but used a more sophisticated SVM kernel and a different type of input
vectors, based purely on sequence [179].
The notion that protein domains or motifs, such as SH3 domains or coiled-coil
structures, are the fundamental unit controlling PPIs has led to many interesting
observations. Sprinzak and Margalit showed that there is a clear correlation
between the domain composition of a protein and its interactions [247]. Deng
et al. [67], Gomez et al. [103], Kim et al. [150] and Wojcik and Scha¨cter [286]
have all constructed statistical methods, using domain information to predict
PPIs at a better-than-random level. Domain information has also been used to
train SVMs [71]. Betel et al. constructed networks of interacting domains and
mapped those onto known biological complexes and pathways [28].
Recently, Jansen et al. integrated both high-throughput interaction data and
indirect interaction evidence, such as co-expression, cellular function and essen-
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tiality, and created a Bayesian network for the prediction of interactions [132].
During this work a data set, named the yeast “gold-standard”, was created,
consisting of hand curated complexes from the Munich Information Center for
Protein Sequences (MIPS) [187]. This data set has served as a benchmarking
set in other work [179]. A similar approach, but aimed toward prediction of
human PPIs, has also been published [220].
Data preparation in PPI prediction is a difficult task for two main reasons. First:
instead of performing analysis of a set of single sequences, one must now focus
on a pair of sequences at a time. This makes all data handling, such as database
searches, sorting and filtering much more complex, as well as rendering standard
methods of redundancy reduction and balancing useless. Second: there is no
available set of unbiased, decidedly negative data; pairs of proteins that do not
interact when coexisting in time and space. Such negative data is crucial for
the training of most types of machine learning algorithms.
While the first-mentioned problem is quite an obstacle, it can be overcome with
computing power and new algorithms. The second problem is much greater and
a large part of our work described here deals with the definition and handling of
negative interaction data and also how improper selection of negative training
data may have affected previous attempts at PPI prediction.
Results
Pitfalls of previous attempts at negative data definition
As pointed out in the introduction, several groups have attempted to create
methods to predict PPIs. The lack of negative training data and the high error
rate of positive data complicates the task and there is reason to question many
claims for high performance PPI prediction methods published as pointed out
by Ben-Hur and Noble [22] and the following sections.
Combinatorial effect of large complexes
When interpreting complex pull-down data, using the “matrix” representation
can result in a combinatorial explosion of pairwise interactions derived from
large complexes.
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Some of the previous attempts [132, 179, 175] have made use of the MIPS com-
plex tables [187]. While these data are manually curated and of high quality,
the combinatorial effect of the matrix representation of large complexes inher-
ently biases the data. The single, largest complex, the ribosome, with almost
10,000 possible PPIs among its ∼140 proteins, using the matrix representa-
tion, accounts for ∼60% of the interactions in the “gold standard” set compiled
by Jansen et al. Ribosomal proteins have specific features and properties and
are conserved in sequence [96], so when using such data as input for a predic-
tion method, along with functional annotations, sequence information and/or
information of functional domains, there is a risk that the methods “learns”
to recognise ribosomal pairs of proteins and in effect, becomes a predictor of
ribosomal protein pairs, rather than a predictor of interacting pairs.
Correlation of sub-cellular localisation, domain composition and bio-
logical process
Several recent machine learning approaches to PPI prediction, mentioned above
[132, 220, 171] pair together proteins from different sub-cellular compartments
(e.g. a plasma membrane protein and a nuclear protein) as non-interacting
pairs for training. While this assignment is presumably correct in most cases,
it is inherently “dangerous” as input to a machine learning method because
sub-cellular location is correlated to many kinds of biological information, such
as amino acid composition [47, 49], protein domain composition [192, 41] and
functional categories [50]. In the approaches mentioned above, information of
sequence and/or functional categories was included as training data, and because
of the correlation between sub-cellular location and sequence/function, it is quite
possible that the method is biased towards sub-cellular location prediction rather
than PPI prediction.
Using a similar approach as Rhodes et al. [220], we determined the likelihood
ratio (LR) of a protein pair being in the positive set vs. negative set given
the size of the so-called smallest shared biological process (SSBP), which is the
entity farthest down the hierarchical Gene Ontology (GO) tree - in other words,
the most specific term - which the two proteins have in common. As positive
data we defined all human protein pairs from UniProt assigned by GO to either
the plasma membrane or the nucleus. We then identified the SSBP of each
pair and counted the frequencies of each SSBP size. The results are shown in
table 3.3, and show a clear correlation of the SSBP size with the compartment
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assignment. This tells us that physically separated proteins tend to have a larger
SSBP and therefore the negatively defined data Rhodes et al. use are already
biased towards larger SSBPs, tainting this method as a neutral measure of a
protein pairs likelihood to interact.
SSBP GSP GSN Pr(S|GSP) Pr(S|GSN) LR
<10 2,498 76 0.00046 0.00149 0.31094
10-50 20,465 951 0.00379 0.01860 0.20358
50-100 39,984 1,874 0.00740 0.03664 0.20185
100-500 199,367 11,405 0.03688 0.22301 0.16537
500-1000 96,425 11,376 0.01784 0.22244 0.08019
possible 5,405,989 51,142
Table 3.3: Correlation of likelyhood of a protein pair being assigned to the
same compartment and the size of the smallest shared biological process
in Gene Ontology. As can be seen by the LR, it is becomes decreasingly
likely for a protein pair to be assigned to the same compartment as the
size of the SSBP becomes greater.
We also calculated the so-called domain enrichment ratio for all the protein
pairs in assigned to the same compartment (nucleus or plasma membrane) vs.
all pairs where one protein was assigned to the plasma membrane and the other
to the nucleus. We used 2/3 of the data to calculate the domain enrichment
ratio, and the remaining 1/3 to test the distribution of enrichment ratios for
protein pairs from the same and different compartments, respectively. While
we did not see a clear correlation between the domain composition and the
domain enrichment ratio on the whole scale of enrichment ratios obtained, only
pairs assigned to the same compartment were seen having an enrichment ratio
above 30, showing that protein domain pairs seen most commonly occur only
in proteins assigned to the same compartment. All in all, this shows that there
is a clear correlation between the input features and the negative examples in
the approach taken by Rhodes et al. , Jansen et al. and others which make use
of physically separated proteins as negatives for a feature driven classifier.
Random negatives
Yet another possible pitfall in the prediction of PPIs is the definition of neg-
ative data. Non-interacting pairs of proteins are hard to define and several
approaches have been tried in this respect. The simplest approach is to simply
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define all pairs not known to interact as non-interacting [71]. This is a rather
vague definition because of the non-completeness of the available PPI data.
Bock and Gough used shuﬄed amino acid sequences as negative pairs [32] with
good results. However, Lo et al. have assessed the effect of using such artificial
protein sequences instead of real proteins in machine learning approaches [171],
and found that using shuﬄed sequences gives a significant boost in perceived
prediction performance, presumably because the algorithm learns to distinct
between real proteins and artificial ones. It should therefore be avoided to use
such shuﬄed sequences as input to a prediction algorithm.
Feature-based prediction
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Figure 3.5: Sensitivity, specificity, accuracy and Matthews correlation coefficient
plotted against the number of times proteins were allowed to appear in the neg-
ative set of interacting proteins.
Our initial approach using the ProtFun method [135], where calculated, derived
and predicted protein sequence features are combined as input to a neural net-
work simulator, showed great promise. We quickly achieved performance on par
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with previously reported figures using cross-validation, but when running the
method on unseen data, the performance dropped to random, with almost all
previously unseen protein pairs being predicted as interacting. A subsequent
investigation revealed that the method had simply learned to recognise sev-
eral proteins appearing multiple times in the negative set, while predicting all
pairs of other proteins as positive. The graph-theoretical approach to defining
non-interacting proteins (see section 3.3) had a side-effect of assigning isolated,
peripheral proteins multiple times to the negative set.
As figure 3.5 shows, the specificity falls, and sensitivity grows as we allow the
same protein to appear in more negative pairs. This indicates a rise in the
false positive prediction rate and a drop in the false negative prediction rate
caused by the ANNs simply “remembering” the most common proteins in the
non-interacting set and predicting all subsequent pairs including those proteins
as non-interacting and all other pairs as interacting.
We proceeded to construct an algorithm limiting the number of times a given
protein was allowed to appear in the training sets. In order to loose as little
data as possible, instead of setting a hard threshold, we created an algorithm
to balance the ratio of occurrences of each protein in positive and negative data
set. The algorithm uses the absolute value of the logarithm of the ratio of
occurrences of each protein in the training sets as a target function to minimise.
Each round in the algorithm prunes out a single interaction of the protein with
the highest value of the target function and its interaction partner with the
highest count of occurrences in the same set. A flowchart of this algorithm is
seen in figure 3.6.
Using this balancing algorithm, we reconstructed our data sets, keeping the ab-
solute log-ratio of occurrences of proteins within the positive and negative sets
below 1.2. When we then proceeded to train the ANNs, using these redundancy-
reduced data sets, the predictive performance fell dramatically, and we aban-
doned the feature-based approach as, apparently, the ProtFun type features do
not capture the property differences of interacting vs. non-interacting protein
pairs. Having said that, the most important features for PPI prediction, ac-
cording to the feature selection algorithm, are sensible according to published
material on protein-protein interactions. The are: flexibility, disulfide bridge
count, hydrophobicity, secondary structure and tyrosine kinase motifs. These
features were automatically selected in almost all runs of our training and there-
fore are likely to be important to the ability of two proteins to interact. Chain
flexibility (and low count of cysteine bridges, which impose rigidity) was seen to
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promote interaction, which is not surprising. Schlessinger and Rost have shown
that flexible regions, with no regular secondary structure are overrepresented
in promiscuously interacting proteins [233]. Hydrophobicity is not surprising
either, and the first analyses of PPIs focused on hydrophobic patch analysis
[139].
Figure 3.6: The balancing algorithm. A flowchart of the algorithm, used to
balance the number of occurrences of each protein in the positive and negative
training sets. The initial step is to count the frequency of each protein in the
data sets. The ratio of occurrences in the two datasets is calculated and then
the absolute value of the logarithm of this ratio is found as the target value.
The protein with the greatest target value is identified and its interaction with
the protein, having the second- highest target function value, is pruned from the
database. This procedure is repeated until the ratio of all protein occurrences in
the positive and negative training sets is within a given threshold.
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Domain profile approach
As discussed in the introduction, domain profiles have been used to infer in-
teractions between protein pairs. The most common method is to analyse the
frequency of domain occurrences in known interacting pairs and based on those
frequencies, derive the odds of interaction between other pairs. While the proce-
dure is simple and useful, and no non-interacting pairs are needed, it is limited
in the way that large databases of PPIs are needed to derive accurate proba-
bility scores. When analysing interactions between multi-domain proteins it is
also hard to state which domains are responsible for the interaction between
the proteins. Therefore a “smarter” way of using domains as input for a PPI
prediction method is preferable.
An obstacle is the size of domain vocabularies - the largest domain assignment
databases, PFAM and Interpro [20, 193] having several thousand domain defi-
nitions. Such a vocabulary is prohibitively large for machine learning methods
such as neural networks (ANNs) and support vector machines (SVMs) and re-
sults in long training times and complex network structure and requires large
training data sets.
Recently, a novel training algorithm for SVMs was published [138], which allows
training of a prediction method in time which grows linearly with the number
of non-zero dimensions in the input vector. This is ideal for domain interaction
vectors, which have a high dimensionality (the total count of domain definitions
squared), yet they are very sparse (only a few of these vectors are non-zero -
the product of the number of distinct domains in the two proteins).
We proceeded to create such domain interaction vectors, figure 3.7 shows the
procedure of encoding the domain interaction matrix for a pair of interacting
proteins. Using 10-fold cross validation, we reached a Matthews correlation
coefficient of 0.5387, comparable to the training results of the feature-based
approach discussed earlier. However, independent validation in the form of the
yeast complex data from Gavin et al. [97] led to much higher scores than the
feature-based ANNs. The results are seen in table 3.4.
At first inspection the method’s performance on negative data seemed good,
with 10 correct negative predictions for every false negative. The results on
positive, however, data were not as good, as only 1 out of 8 true interactions is
captured, reducing the value of this approach as a de novo predictor of PPIs.
Furthermore a lack of domain definitions for about two thirds of the validation
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Data Specificity Sensitivity Accuracy Matthews CC
Cross validation 0.8735 0.5040 0.7838 0.5387
Cellzome 0.2669 0.7699 0.7325 0.3367
Table 3.4: Results from our domain-based SVM approach, both cross validation
on our balanced training set and independent predictions on the data from Gavin
et al. [97].
data set renders the majority of data useless in this case. Domain profiles
for interacting pairs of proteins obviously hold predictive information about
interactions, but result in low yield.
Discussion and future work
Data handling is tricky when working with pairs of sequences instead of the usual
singles. Database queries, homology reduction and vector encoding for machine
learning algorithm input are cumbersome and complex. We have identified a
number of possible pitfalls in the handling of PPI data we believe have influenced
previous results on PPI prediction. We produced a training set of unbiased data
and defined non-interacting pairs of proteins with the help of graph theory.
We constructed a novel balancing algorithm to homology reduce the positive
and negative training sets maximising the amount of remaining pairs and we
finally assembled prediction methods based on protein features using neural
networks and domain composition using support vector machines. The feature-
based PPI prediction approach yielded no useful results, while the domain-
based approach seems more appropriate, but is hampered by low specificity
on validation data, assigning most protein pairs as non-interacting. There are
numerous data types which could be added to the PPI prediction model, such as
sub-cellular location, functional category assignment, genetic evidence such as
co-evolution and homology. Several previously published methods have made
use of such data [132, 220]. In our search for a sequence or sequence-motif-
based method to predict PPIs, we have refrained from using such data. In
fact we have rigorously filtered our training data to exclude any sort of bias,
due to sub-cellular location incompatibility, multiple occurrences of individual
proteins/complexes etc. as we feel a sequence-based approach should. Our
results indicate that protein features, which have proved successful in describing
protein functionality in previous research [135] do not capture the essence of
protein-protein interactions. Our domain-based effort were a bit more successful,
80
3.3. Paper III: Perspectives on protein-protein interaction prediction
yet not very useful as lack of domain definitions render this approach useful in
only a third of the cases, and even then, the method is clearly biased to predict
most pairs as non-interacting.
The sequence derived features used in the ProtFun approach do not seem to cap-
ture the nature of interacting proteins. This may not come as a surprise as pro-
tein binding is surface- and three-dimensional-structure-specific, and sequence-
based methods have never been successfully applied to the problem of predicting
protein structure. Protein domain definition usually carry structural informa-
tion, and in that information the success of domain-based efforts may lie.
Many groups have attempted prediction of PPIs in the last few years, with
varying results. It is worrying that the benchmarking data used in many of
those attempts are flawed and as Ben-Hur and Noble conclude: “...prediction of
protein-protein interactions from sequence is a difficult problem that can still
be considered unsolved” [22]. A statement that we fully agree with as a result
of our own experiences.
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Figure 3.7: Encoding of domain interactions to a sparse vector for SVM training.
For a given pair of interacting proteins (or non-interacting in the case of the
negative data set), A and B, we scan the proteins for domains and create a
matrix of all possible domain interactions (all domain database entries included).
We then “flatten” that matrix out to a bit vector, which is the input for the SVM
training.
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Materials and methods
Positive data
We used integrated data from the STRING database, taking advantage of the
fact that STRING has implemented a quality score for PPIs and that STRING
is an integrated resource, where there should not be a bias towards any one
evidence type, organism or experiment. To set out with a high-quality data
set, we chose to use only interactions with a STRING score above 0.8. We also
chose to limit ourselves to budding yeast as a model, hoping to later expand our
research to other, less studied organisms (PPI-wise) such as man. This initial
data set contained 7324 interactions from complex pulldown experiments, using
the spoke interpretation of experimental data.
Negative data
We tried to avoid pitfalls such as the ones described above in order to produce a
negative data set of non-interacting proteins, not different from our positive data
pairs in any way, such as complex-specificity, compartment bias or biological
genuinity of the sequence. We turned to graph theory for definition of negative
examples, assembling all the positive interactions we could get our hands on
into a graph, and then selecting those protein pairs which were furthest apart in
the network. To prevent compartment bias we filtered those pairs out of the set
where the two proteins were not annotated as having been experimentally seen
in the same compartment. The network distance was set to a minimum of 4
edges, which yielded 41,271 protein pairs to work with as non-interacting pairs.
After running our balancing algorithm with a maximum absolute log frequency
ratio of 1.2, 5281 protein pairs remained in our negative training set. Obviously,
this method will only work on a reasonably complete interaction graph, as new
links in the network may shorten the distance between any two proteins and
disqualify the pair according to our definition of non-interacting pairs. While
we believe that the method is valid in budding yeast, for which there have been
published on average 10-20 PPIs pr. protein, it may not translate well to other,
less studied organisms.
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Feature encoding and selection
We applied the ProtFun method of feature-based functional prediction for pro-
teins [135]. Feature vectors were calculated/predicted for each protein in the
data sets and then concatenated for each pair appearing in either the positive
or negative data sets. Using all features as input to a learning algorithm does
not necessarily produce the best biological discriminator. As described in [135],
training an ANN on smaller subsets of feature combinations will most of the
time result in much better predicting performance than an ANN which has
been trained on all features (the complete feature vector). The idea is to re-
duce the input space to combinations of features which in concert contribute
high discriminatory value. We applied both a heuristic and a genetic algorithm
for feature selection and trained ANNs using an optimal input of 7 features.
Each pair of proteins was presented twice to the networks switching the order
of proteins between the runs.
For the domain profile-based SVM approach, we created a contingency ma-
trix for every possible domain-domain interaction, given a pair of interacting
proteins. This bit matrix was then flattened into a single, sparse vector and di-
mensions that were never seen to be non-zero were pruned out for performance
reasons.
ANNs
We used feed-forward type networks using backpropagation to update the weights.
Training was performed with threefold cross validation.
SVMs
We used the SVMlight package including the latest linear, structural SVM train-
ing algorithm [138]. Training was performed with tenfold cross validation.
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3.4 Whole proteome interaction maps
As discussed in this chapter, the low reliability of PPI data, especially high-
throughput data, shows the potential benefits for prediction methods for PPIs.
Several approaches have been taken in this respect, but method comparison is
difficult and results are easy to tweak with improper benchmarks and biased
input data, as well as hard to validate.
As more and more PPI data are assembled, a network structure emerges and
network analysis is a whole science in itself. The next chapter includes discussion
about graph-theoretical methods to validate and score PPI networks on both
local and global scale.
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Let us now take a look at the structure of sequence components which emerges
when integrating various data types, superimposed on the frame of protein-
protein interaction networks.
Several complex structures, such as hyperlinks on the Internet, social contact
networks, disease propagation and electrical circuits have been modeled using
networks [64, 279, 4, 18]. The huge networks that have emerged from protein
interaction data have been the subject of much research in the last years, rang-
ing from simple guilt-by-association transfer of annotations between physically
interacting proteins to complex large scale graph-theoretical studies.
In the framework of the disease gene finding group at CBS, a warehouse of
protein-protein interaction data has been constructed, integrating interaction
data from most or all of the large interaction databases mentioned in chapter 3
as well as derived interactions such as pathway neighbors in KEGG [144] and
Reactome [141] as well as orthologous interactions between different species.
This huge resource, called Inweb, contains over 300,000 interactions in humans.
Similar data sets have also been produced for model organisms such as bud-
ding yeast, fruitfly and nematode. These huge networks help us identify local
functional modules and proposed interconnections when searching for disease-
causing genes, as explained in section 4.2. Analysing the their global structure
from a systems point of view is also interesting.
In contrast with the reductionism applied when performing analysis and an-
notations of the protein and gene components of cells, the network analysis of
the interactome tends to take a birds-eye view of the data, integrating more
and more information and will hopefully at the end produce a model that can
explain systems of biological entities working in unison: a complex, a pathway,
a regulatory mechanism, the cell.
This chapter contains some theoretical background on network theory as well as
network analysis of the human interactome, focusing on specific chromosomes
in hope to find clues to the mechanisms that govern chromosomal diseases such
as trisomies. The chapter is concluded with a research paper on disease gene
prioritisation. The paper revolves heavily around two networks, the human
interactome and the phenome, a network of phenotype descriptions, where links
are made by text mining disease descriptions and finding term overlap.
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4.1 Graph theory for the biologist
In chapter 2 we saw all sorts of annotations being attached to the components
of genes and proteins. Similarity in any of these annotation spaces, such as the
localisation, co-expression or regulatory levels can be viewed as links between
the components, as can more direct physical links as direct protein-protein in-
teractions or metabolic reactions. An assembly of the components and links
from any of these spaces can thus be pictured as a network showing the step-
wise connections between all components. Such networks are not only useful to
visualise a large number of components and their interconnections, there is an
entire mathematical discipline devoted to the analysis of networks: graph theory
[69]. This section should give readers a bit of background on subject.
4.1.1 Terminology
A network, or graph, is a collection of nodes and edges. For our purposes a node
represents a protein or gene and an edge represents a link between nodes, imply-
ing a connection on some level, be it a direct physical interaction or a similarity
in phenotypic description when the two genes or proteins are dysfunctional or
something third and completely different.
In this section I will try to explain the general terms in graph theory, that have
been related to biology, in an understandable language, leaving the math out as
far as possible. If mathematical definitions and notations are of interest, readers
are referred to [69].
Directed vs. undirected edges
One of a network’s most important properties is whether or not it is directed,
meaning whether or not an edge from node A to node B implies a reciprocal edge
from node B to node A. Directedness results from, e.g., temporal order or some
other irreversible action between the components, making the step from A to B
possible, but the step back from B to A impossible. An example of networks
often modeled as directed graphs are metabolic networks, where metabolites are
chemically and (practically) irreversibly modified. Undirected networks model
components and links between them, where the step between A and B is equal
to the step between B and A or that the edge between A and B is unrelated to
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temporal terms. A graph modeling physical interactions in a protein complex
is an example of a network that would generally be undirected, as there is little
sense in applying direction to the structural interface between the two proteins.
Node degree
A node’s degree, or connectivity, is the number of edges connecting that node to
other nodes. For a directed graph, the degree can be split into out-degree and
in-degree, meaning the number of edges starting at the node and the number of
edges terminating at the node, respectively. Nodes with a high degree are often
termed hubs. Although there is no formal definition of how many connections
a node must have to qualify as such, Jeong et al. contrasted proteins with
≥ 15 connections with those having ≤ 5 connections as hubs and non-hubs,
respectively [137]. Ekman et al. defined hubs as proteins with ≥ 8 interactions
and non-hubs as those with less than 4 interactions [78].
Path lengths
The path length between two nodes in a graph is simply the number of edges
separating the nodes. In a given graph, there may be several paths possible
between two nodes. The shortest path, or geodesic, between two nodes is the
the path between those nodes (there can be more than one), containing fewest
links. The diameter1 of a network is the average of all the pairwise shortest
paths in the network [137]. A node’s eccentricity is the length of the longest
path from that node to any other in the network.
Clustering coefficient
The clustering coefficient of a node measures how many connections there are
between the node’s neighbors as a ratio of the possible maximum number of
connections. This is given by Cn =
2e
k(k−1) , where n is the node under inspection,
e is the number of edges observed between any of n’s neighbors and k is the
number of neighbors n has.
1In classical graph theory, the diameter is defined as the maximum of the shortest paths
in the network [213].
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4.1.2 From topology to biology: global topology
The last section introduced some of the concepts that are used when dealing with
graphs. Most of these relate to individual nodes and edges in the graph. When
analysing graphs on the size order of the entire human proteome and interactions
between the protein components, it is useful to have measures that describe the
network and subnetworks as a whole and not just the individual nodes and
their links. Analysing the network structures that emerge when integrating
omics data is one of the biggest and most interesting tasks in systems biology.
Network models and topological measures
Around 1960, Erdo¨s and Re´nyi constructed a model for random networks where
links are placed with equal probability between any two nodes [84]. As a result,
the connectivity of the nodes in such networks follows a Poisson distribution (fig-
ure 4.1(a)). A property of these networks is that they are small-world, meaning
that one can move from one node to any other by traversing only a minimal
number of links. In mathematical terms the diameter of small-world networks
is proportional to the logarithm of the network size.
Empirical observations of www hyperlinks, social contact networks, electrical
circuits, and various biological networks, such as interaction networks, metabolic
networks, and regulatory networks [18] have revealed that the global topology
of these real-world networks differs from the Erdo¨s-Re´nyi model, particularly,
the connectivity distribution follows a power law: P (k) ∼ k−γ , γ > 1 (figure
4.1(b)). In order to quantify the statistical significance of the structure of many
real world graphs, Baraba´si and Albert introduced a new graph model: the
scale-free network [19], in which new edges preferentially attach to proteins
with a high connectivity; hubs. It has been shown that many biological graphs,
as well as the Internet hyperlinks and social networks better fit the scale-free
model than the Erdo¨s-Re´nyi model [137, 4, 18]. Scale-free networks are what is
known as ultra-small-world, meaning that every two nodes are joined by a path
even shorter than those in random networks; their diameter is proportional to
log(log(N)), where N is the network node number2 [52, 56].
2Actually, the log(log(N)) correlation is seen for power-law degree distributions where the
exponent ranges from -2 to -3. Practically all scale-free networks inspected here qualify as
such.
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The new Baraba´si-Albert scale-free model has sparked much interest and a num-
ber of publications on networks. The concept of such heavy-tailed probability
distributions is, however, by no means new [145]. Used to describe land own-
ership in Italy over 100 years ago by Pareto, such distributions were used as
basis of Yule’s mathematical models of “preferential attachment” in 1925 [294]
and such “rich get richer” distributions were analytically described by Simon in
1955 [237] and later used to analyse scientist citation networks [64, 63].
(a) Erdo¨s-Re´nyi (b) Scale-free (c) Hierarchical
(d) Erdo¨s-Re´nyi (e) Scale-free (f) Hierarchical
Figure 4.1: Upper row: degree distribution P (k). For Erdo¨s-Re´nyi networks,
the degree probability follows a Poisson distribution, while for scale-free and
hierarchical networks, the distribution follows a power law, indicated by a straight
line with a slope of −1 on a log-log plot. Lower row: clustering coefficient C(k)
as a function of degree. The clustering coefficient is not correlated with node
connectivity in Erdo¨s-Re´nyi and scale-free networks. A slope of −1 on a log-log
plot of C(k) is an indication of hierarchical structure. Inspired by [18].
Despite having a probability distribution of connectivity that favors hubs, a
feature of PPI networks is that they contain a large number of clusters. The
concept of heavily interconnected clusters may seem in direct opposition with
the scale-free model, where few hubs direct the topology of the network. Yet, it
has been shown that interaction maps, that display a degree distribution charac-
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teristic of scale-free networks, also contain functional modules [113]. Scale-free
nature and modularity can be explained with hierarchical modularity [293, 217],
where disjoint clusters form increasingly larger clusters. Hierarchical networks
display scale-free properties, such as a power-law distribution of node connec-
tivity, and at the same time the clustering coefficient in such networks shows a
correlation with the node degree, which is not seen in regular Baraba´si-Albert
scale-free networks (figure 4.1(f)) [293, 18].
A recent publication argued that protein interaction networks are better mod-
eled by geometric networks than the scale-free model [213]. Khanin and Wit
statistically challenge the scale-free model as suitable for protein networks [148].
The geometric model implies that there are spatial constraints to the probability
of two nodes being linked. While there undoubtedly are constraints to which
proteins can interact, it is unclear how to best model these. The assumption
that protein interaction networks are scale-free has also been challenged on the
basis that the underlying data are incomplete and that Erdo¨s-Re´nyi and other
network models cannot yet be ruled out as fitting [109, 252]. Keller also criti-
cises the global acceptance of scale-free distributions as some sort of global laws
that governs most complex systems from our cells’ proteins, to our sex lives to
the Internet [145]. This is indeed an important point in today’s network anal-
ysis of cellular data; the results so far are based on empirical observations and
the data are known to be notoriously biased, incomplete and full of false posi-
tives [276, 134]. The dynamics, that underlie the properties displayed by these
networks, will hopefully be better explained as they gain more experimental
coverage.
Different experiments - different networks
The CBS data warehouse stores a large amount of protein-protein interaction
data, both experimental and computationally derived. This resource, Inweb, is
described later in section 4.2. The Inweb comprises 3 main data types: spoke,
matrix and binary interactions which have been assigned to their categories by
hand curation of experimental evidence. The spoke and matrix data are derived
from complex pull-downs where pairwise interactions are derived from purified
complexes. As described in chapter 3 there is a great difference in the resulting
set of derived interactions; the spoke model may reduce the number of false
positives, but may also miss a number of true interactions, whereas the matrix
model includes all the possible interactions at the risk of producing many false
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positives. While the matrix model can be viewed as a continuation of the spoke
model for hypothetical pull-downs of all the proteins in a given complex, a
combinatorial problem arises for large complexes, as the number of interactions
grows as the square of the number of proteins. E.g. a complex containing 100
proteins would give rise to 4950 matrix interactions, while the spoke model only
yields 99. The so-called binary data are Y2H data and small-scale experiments
where there is evidence of direct physical contact between the two proteins.
Figure 4.2 shows the results of our network analysis of the whole Inweb of human
interactions. The degree distribution agrees with prior publications [101, 293]
and displays scale-free properties as described in the previous section (a). The
clustering coefficient shows correlation to node degree, which is indicative of a
hierarchical structure in the network (b). This is most prominent in the binary
interaction network. The third plot shows the average neighbor connectivity
as a function of connectivity (c). Maslov and Sneppen have shown that yeast
Y2H data has a declining slope on such a plot [180] which tells us that hubs
tend to be disjoint and therefore the network is disassortative. The complex
data tell a different story as both matrix and spoke interpretation of Inweb data
show a rising tendency of hub interconnections until a connectivity of 10 and
100 is reached for spoke and matrix models, respectively, implying assortativity
of hub proteins. In the case of matrix interpretation, this is understandable as
large complexes will result in all the constituent proteins being interpreted as
interconnected hubs, but seeing this effect in spoke data as well indicates that
this is not just a combinatorial artifact, but a fundamental difference between
networks constructed with CP data on one hand and Y2H data on the other.
This underlines the point that one must think carefully of what the network
,one uses to model complex systems, is meant to describe, and not to jump to
conclusions from network analysis of incompatible data.
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Figure 4.2: (a) Degree distribution in the human interactome network. All 3 data
types: matrix, spoke and binary display degree distribution following a power law
implying that they are scale-free. (b) Clustering coefficient (C(k)) as a function of
connectivity. Correlation of C(k) implies hierarchical structure of the network. All
3 networks show this tendency, but it is strongest in the binary network. (c) Av-
erage neighbor connectivity as a function of node connectivity for human protein
interactions. Such data for Y2H experiments in budding yeast have previously
been shown to follow a declining slope on a log-log plot [180]. This trend is also
seen in our data for human binary interactions, which are mostly derived from
Y2H experiments. This suggests that such networks are disassortative, meaning
that highly connected proteins are less likely to be connected. For complex pull-
downs the picture is quite different: both spoke and matrix interpretations yield
a curve which has a maximum value, indicating that hubs have a tendency to
connect to other hubs.
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4.1.3 Chromosomal interaction maps
This section describes work at CBS, where we have tried to use global topology
measures, described in the last section, to quantify and analyse the interaction
maps of individual chromosomes in the human genome. Ultimately our goal
with this ongoing work is to identify discrepancies in the network structure of
different chromosomes that may explain karyotype-phenotype relationship in
chromosomal aberrations such as trisomies and some forms of cancer.
Chromosomes and phenotype
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Figure 4.3: Gene counts for all human chromosomes as annotated by the Ensembl
genome browser (http://www.ensembl.org). The severity of developmental ab-
normalities of multiploidies 13, 18, 21 and of the Y chromosomes is correlated
with the number of genes present on the chromosomes.
Multiploidy, or polyploidy, is the genetically unnatural state of having more
than the usual two copies (in the case of autosomes, one in the case of the
sex chromosomes) of each chromosome in the cell´s nucleus, usually resulting
from the failure of chromosomal segregation during cell division of gametes.
By unknown mechanisms, this state is usually lethal, presumably because of
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an excessive copy number of the genes encoded on the chromosome present in
multiple copies.
While most forms of polyploidy in humans are lethal, leading to spontaneous
abortion, some are viable, namely the trisomies of chromosomes 13, 18, 21 and
polyploidy of the sex chromosomes. Trisomy of chromosomes 13 and 18 is ac-
companied with severe defects and the affected individuals usually die shortly
after birth but may reach their teens in some cases [21]. Trisomy 21, the most
common cause of Down syndrome, has a complex phenotype of 71 described
traits, including mental retardation, congenital heart defects, and a special for-
mation of the face and hands [83]. Male X and Y diploidy and female triple X
are known polyploidies, with mild phenotypes [223]. In the case of triple X, two
Barr bodies3 are formed instead of one. Males having the XXY constitution
are usually tall, having androgynous features, and there are reports that this
karyotype induces learning disability [223]. From 1965 to 1980, a number of
studies were performed, linking XYY constitution with everything from tooth
size to height to psychological problems and criminal behavior. Some evidence
exists that the correlation with tooth size [7] and height [200, 151, 79] are real.
The most common common cause for aneuploidy is maternal meiotic non-
disjunction [195]. The relative frequencies of non-disjunction are not random,
but chromosome-specific with trisomy 16 as the most common form of ane-
uploidy. Maternal age is the only known risk factor in chromosomal non-
disjunction, but the functional mechanism of this risk factor is unknown [195].
The viability and severity of the phenotype of the individuals suffering aneu-
ploidy seems to be correlated with the number of genes on the chromosome
with anomalous copy number, with a less severe condition being observed for
chromosomes with a lower number of genes. Figure 4.3 shows the number of
genes assigned to each human chromosome.
Aneuploidy and cancer have often been correlated and recently, a theory impli-
cating cancer as a chromosomal disease, originally put forth over 100 years ago
[110, 35], has been revived [75, 76]. If aneuploidy turns out to be a cause, rather
than result, of some forms of cancer, a systems view of the chromosomes may
aid cancer research and treatment in the future.
3In females, one of the X chromosomes is rendered inactive and forms a dense structure ,
known as a Barr body, peripherally in the nucleus.
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Chromosome network topology
Using the Inweb network of experimental and derived protein interactions in
humans, we extracted the subnetworks that correspond to single chromosomes.
We then analysed the lists of chromosomal genes one at a time to see if any
striking differences in network topology were observed.
Working from the hypothesis that genes are not essential by themselves, but
rather take part in essential reactions and form vital complexes [115], we have
looked at the interaction maps of individual chromosomes to see whether there
is any evidence that the viability and severity of multiploidies could be related
to topological effects in the interaction networks of these chromosomes.
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Figure 4.4: Left: The degree distribution of the proteins on human chromosomes.
While there are small differences, the slope on the curve is approximately the
same, indicating that the degree distributions for the chromosomes follow power
laws with similar exponents. Right: Average neighbor connectivity as a function
of node connectivity. While previous reports indicated that neighbor connectivity
showed a declining trend as the degree of the node increased [180], we find that
the affinity of hubs to interact with hubs actually increases with hub size, up to
degree ∼ 100. This trend is shown for the full interactome, as well as individual
chromosomes and is reproduced with yeast and fruitfly data (not shown).
Figure 4.4 shows the connectivity distribution of the human interactome, chro-
mosome by chromosome. While the chromosomes with the lowest gene count
also have the lowest connectivity, protein-wise, the slope of most of the lines is
approximately the same, indicating that the chromosomal connectivity distri-
bution follow the same power law.
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Conservation of proteins
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Figure 4.5: Normalised number of orthologous genes grouped by the chromo-
some they map to in humans. The blue bars denote genes from budding yeast,
the yellow ones fruitfly genes and the red ones are genes from the C. elegans
nematode.
Another hypothesis tested was that genes, conserved between species, are more
likely to be essential than others and that the ratio of such conserved genes gives
clues to the severity of chromosomal aberrations.
We assembled sets of orthologous proteins in budding yeast, fruitfly and nema-
tode, and analysed which chromosome they mapped to in the human genome.
Figure 4.5 shows the number of orthologous proteins normalised by the number
of genes on the chromosome. The viable polyploidy chromosomes Y, 21, 18 and
13 do have a low ratio of orthologous proteins to these organisms, yet this is
hardly conclusive evidence, as chromosomes 15 and 7 also show low ratios of
orthologous genes to these species.
99
Chapter 4. Networks
Physical proximity of genes encoding interacting proteins
In an attempt to see which chromosomes are most important for the human
interactome, we mapped the chromosomal origin of all the PPIs in Inweb. Fig-
ure 4.6 shows the number of interactions between chromosomes, pairwise, nor-
malised by the product of the two chromosomes’ genes (except in the case of
the same chromosome). The chromosomes are ordered by the number of genes
residing on them to reveal, if any, size effects. Chromosomes 12, 17 and 19
have a higher than average count of interactions between them. Strikingly the
fields along the diagonal are systematically darker than average, indicating that
proteins are more likely to interact intrachromosomally, rather than interchro-
mosomally. This effect is seen, using all PPI data combined, as well as by
separating matrix, spoke and binary data types. We also created interaction
networks for chimp, budding yeast, fruitfly and nematode as well to see if this
effect could be reproduced in other organisms , and in most cases it is although
the pattern is not so obvious in the case of the nematode as can be seen in figure
4.7.
The reason for this bias towards interchromosomal interactions is probably bet-
ter co-regulation of interacting or functionally similar genes. Chromosomal co-
location of functionally similar genes has been established before [55] and the
same goes for genes that take part in the same pathway [167]. Co-expressed
gene clusters have been shown to co-locate on chromosomes in mice [188] and
there is a correlation between co-expression and interactions between proteins
[99, 130, 132]. All these data and more were analysed by Teichmann and Veitia,
who concluded that “genes encoding subunits of stable complexes are clustered
on the yeast chromosomes” [258].
4.1.4 From topology to biology: local topology
After zooming out to view whole interactome maps, we now move from global
topology to local topology. Most proteins work in concert with a number of
other proteins to form a pathway or a complex [113, 164, 216, 121, 114, 236]. A
great deal of research has focused on identifying such functional modules. Two
main approaches have been followed, either focusing on biological descriptions
of of proteins that are interconnected in interactomes or aiming at identifying
statistically significant patterns in networks.
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(a) Human (b) Human matrix data
(c) Human spoke data (d) Human binary data
Figure 4.6: All-pairwise count of genes encoding interacting proteins, mapped to
chromosomes and normalised by the total number of possible interactions. Note
the dark fields along the diagonal, indicating that proteins are more likely to
interact with other proteins from the same chromosome than they are to interact
with proteins from other chromosomes. This striking effect is seen in all PPI data
types.
Centrality and essentiality
Centrality is a collection of terms in graph theory, relating to a node in the
network. The centrality can be based on the degree of the node (degree cen-
trality), the path length to other nodes (closeness centrality), its placement in
the paths between other nodes (betweenness centrality), and other topological
101
Chapter 4. Networks
(a) Chimp (b) Budding yeast (c) Fruitfly (d) Nematode
Figure 4.7: All-pairwise count of genes encoding interacting proteins, mapped to
chromosomes and normalised by the total number of possible interactions. From
left: chimp, budding yeast, fruitfly and nematode worm. The diagonal effect,
indicating that interactions are biased towards proteins encoded on the same
chromosome is seen for all organisms.
measures. The measures differ in directed and undirected networks, but the
basic understanding of the terms is the same.
In general, the theory is that the greater a node’s centrality, the more impor-
tant it must be in the network. The scale-free nature of biological networks
implies that there is an over-representation of hubs, nodes with a large number
of interactions, which, by definition, have a high degree centrality. Such nodes
have an important role in the graph structure, and hence also in the biological
processes that underlie the links connecting the nodes. A hub in a metabolic
network can be assumed to play multiple roles in metabolic pathways, examples
of such hubs are multi-purpose kinases. Han et al. have identified two types
of hubs in protein interaction networks: date and party hubs [108, 61]. Date
hubs are named so because they interact with one partner at a time, temporally
speaking, while party hubs are shown to interact simultaneously with many or
all of their interaction partners.
Resulting from their topology, scale-free graphs have properties that are very
robust to removal of random nodes, as these are most probably nodes with low
connectivity. Targeted removal of the hubs, however, has devastating effects on
the structure of the network [4], leading Jeong et al. and Han et al. to conclude
that degree centrality and protein essentiality are correlated [137, 108]. He et al.
have proposed that such central proteins should not be considered essential by
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themselves, but that they participate in more essential interactions than other
proteins making them indispensable [115]. Sneppen and Maslov have recently
found, that there is actually a negative correlation between essentiality and
centrality in regulatory networks [181].
Topological scoring of protein-protein interactions
Realising that interacting proteins often cluster together, in the error-prone
protein-protein interaction data, several labs have proposed topological scores
to validate and clean these data [227, 228, 97]. We have used such methods to
score our computationally derived network of protein-protein interactions 4.3.
Making use of the fact that interaction networks have a prevalence of hubs,
Lappe and Holm have suggested to use a greedy algorithm to identify the nodes
with a highest connectivity, not yet used as baits in interaction experiments
[163]. They suggest that targeted experiments, using these highly connected
nodes as baits, may provide 90% interactome coverage while only using 30% of
the proteome as baits.
These algorithms rely upon knowledge of the network topology and obviously
require as complete a network as possible for optimal function. As with many
other properties of biological networks, they are based on empirical observations
and benchmarks against known sets of interactions.
Motifs and statistical significance
As mentioned above, the models used to describe interactomes are based on
observations and empirical data, and as such, constructed to understand the
structure of real-world networks, rather than explaining them. Recently, these
models have been used to assess the statistical significance of network struc-
tures. Such analysis is heavily dependent upon using a correct model and as
discussed in the last section, a consensus has not been reached on the back-
ground distribution of interaction networks. Therefore, such statistical results
must be viewed with skepticism.
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Complete cellular networks are huge and in many cases we want to step down
and identify smaller elements, or subnetworks4 , commonly known as motifs.
A classic motif example is a fully connected subnetwork - a clique - where
all components are connected to each other. A protein complex with physical
interactions between all subunits will be represented by such a structure in
an interaction graph. Clustering algorithms aim at finding such completely or
heavily connected subnetworks [82, 13].
An attempt to assess the statistical significance of a given motif or subgraph, a
background model is needed. The scale-free model put forth by Baraba´si and
Albert is usually considered the most proper model to date. A typical workflow
to estimate the significance of a particular motif is to:
1. Select a motif from the network
2. Count the times the motif occurs in the network
3. Create a large number of random networks using the same topological
model as the network being inspected (usually scale-free)
4. Count the times the motif occurs in the random networks
5. Assess whether the motif is significantly overrepresented in the original
network compared to the random networks
Simple as it may seem, this is an enormous computational task. Selecting 3
nodes from a network of 1000 nodes yields well over 100 million possibilities,
and going from those 1000 nodes to the whole human interactome with over
20,000 proteins, the possibilities grow enormously. Finding identical motifs in
graphs and subgraphs is also a very complex problem. Several groups have
tried to solve the problem using subset sampling and heuristics to minimise the
computational time involved [189, 281].
Statistical results are only valid if an appropriate background model is chosen as
a comparison. Usually the scale-free model is chosen, where the only constraint
on new edges is that they are more probable to attach to hubs that already have a
high number of edges. Real-world networks may be subject to more restriction
that so. Scale-free networks have been used to model the neural connections
in C. elegans and food webs and as a result several motifs were reported to
4A subnetwork is a substructure of a network, containing only nodes and links from the
original network. Motifs are subnetworks that are significantly more common in a network
than expected by random.
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occur significantly more often in these networks than in corresponding random
scale-free graphs [189]. Those publications do not take into account the spatial
position of neurons, in the nematode nervous system or the placement of animals
in food webs, as pointed out by Artzy-Randrup et al. in [9]. Yet it is intuitive
that the farther apart in the system two neurons are, the less likely they are to
be connected. The same goes for animals in ecological food webs.
The hierarchical clustering of PPI networks has been demonstrated in [217] and
[101] and in the previous sections (4.1.2). Giot et al. proposed that this hi-
erarchical nature was two-fold: the interconnections within clusters and then
the network of interconnections between clusters. A similar viewpoint can be
reached for the dynamic assembly of complexes. de Lichtenberg et al. [61]
showed that complex formation is constrained in both space and time. Such
constrains undoubtedly also apply to the higher level of cluster interconnections
in the interactome, where physical barriers, such as cellular membranes, as well
as co-expression compatibility must be acknowledged when performing large
scale analysis.
Eukaryotic cells are physically divided into compartments, such as the nucleus,
endoplasmic reticulum and mitochondria, by membranes. Such membranes
compose a natural barrier to interactions between proteins, that reside in dif-
ferent compartments. As proteins are targeted to specific organelles, this com-
partmentalisation of proteins leads to a spatial bias in the interactome, which,
as of yet, has not been accounted for in the background models for calculations
of statistical significance of motifs. Figure 4.8 shows the inherent danger of
modeling the interactome as an unconstrained network. A randomised version
of a constrained network looks a lot less clustered and, when used as a null
model, may artificially boost the significance of the motifs found in the original
network. There are both spatial and temporal constraints on the possibilities of
two proteins interacting and one must account for these to create more realistic
null models when assessing subnetwork significance.
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Figure 4.8: These diagrams show a very simplified overview of a eukaryotic cell
with 3 organelles: the nucleus, endoplasmic reticulum (ER), and mitochondrion.
A membrane physically separates the organs from the cytoplasm. The small cir-
cles represent proteins and the lines interactions between those. Many proteins
are targeted to a specific cellular compartment and thus, no interactions will oc-
cur between proteins in separate organs as seen in diagram A, on the left. On
the right, the interactions have been randomised, to a point, while maintaining
the connectivity of individual nodes. This is common procedure to make null
models in scale-free networks [189, 281]. Comparing the diagrams shows the
problems of such null models where the constraints of interactions, whether spa-
tial or temporal, are not taken into consideration when randomising the networks.
Compared to the incomplete null model on the right, the experimental network
on the left displays a high level of clustering and therefore motif significance may
be boosted.
106
4.2. Disease gene finding: a case study in data integration
4.2 Disease gene finding: a case study in data
integration
Performing network analysis on protein-protein interaction data may reveal sub-
graphs, or motifs, where the constituent proteins work in synergy in a functional
module [289, 275, 113, 246]. Thus, functional information may be derived from
protein-protein interaction maps via topological analysis. CBS’ disease gene
finding group has worked on the problem of assigning priority rank to candidate
genes in hereditary human diseases for the last few years.
Working from the hypothesis that proteins function in a modular fashion and
that a loss of functionality - stemming from mutation, incorrect folding or other
problems - in any of a functional module’s constituent proteins renders the whole
module dysfunctional, resulting in similar disease phenotypes.
This following paper is the result of the work of the disease gene finding group
at CBS. The paper naturally belongs at the end of this text, not only this chap-
ter, but the whole thesis, because it is a showcase for almost all types of data
integration and analysis discussed in this thesis. It represents a case study in
biological data integration, data warehousing as well as federation of several
types of annotations. Data formats as different as raw text and structured PSI-
MI XML data are combined using machine learning and statistical approaches.
Phenotype annotations are mapped to genes and proteins through text min-
ing and a huge dictionary of gene and protein names and synonyms employed
to expand our coverage of the human interactome as much as possible. The
collection of annotations is glued on a scaffold of a protein-protein interaction
network, composed of data from various sources, ranging from low-throughput,
high-confidence experiments, to computationally inferred interactions from dif-
ferent species. The resulting phenome-interactome is inspected and validated
using network analysis and a list of suspected disease genes is made available to
the community.
At the end of all this data integration a framework emerges, which significantly
improves the success rate of disease gene predicting compared to existing meth-
ods when using known disease genes for benchmarking.
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Abstract
We performed a systematic, large-scale analysis of human protein complexes
comprising gene products implicated in many different categories of human dis-
ease to create a phenome-interactome network. This was done by integrating
quality-controlled interactions of human proteins with a validated, computa-
tionally derived phenotype similarity score, permitting identification of previ-
ously unknown complexes likely to be associated with disease. Using a phe-
nomic ranking of protein complexes linked to human disease, we developed a
Bayesian predictor that in 298 of 669 linkage intervals correctly ranks the known
disease-causing protein as the top candidate, and in 870 intervals with no identi-
fied disease-causing gene, provides novel candidates implicated in disorders such
as retinitis pigmentosa, epithelial ovarian cancer, inflammatory bowel disease,
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amyotrophic lateral sclerosis, Alzheimer disease, type 2 diabetes and coronary
heart disease. Our publicly available draft of protein complexes associated with
pathology comprises 506 complexes, which reveal functional relationships be-
tween disease-promoting genes that will inform future experimentation.
Introduction
Several diseases with overlapping clinical manifestations are caused by muta-
tions in different genes that are part of the same functional module. In such
instances, the clinical overlap can be attributed to mutations in single genes
rendering the complete module dysfunctional [39]. This concept has been ap-
plied to searches for disease genes by several computational methods, including,
for example, schemes based on Gene Ontology annotations and gene expression
data [2, 91, 92, 262, 210, 211, 182, 269, 270, 123, 93]. The advent of proteome-
wide interaction screens in model organisms has revealed the modularity of the
cellular interactome and that many genes exert their functions as components of
protein complexes such as cellular machines, rigid structures, dynamic signaling
or metabolic networks and post-translational modification systems [18].
Analyses involving model organisms, and more recently humans, show that di-
rect and indirect interactions often occur between protein pairs responsible for
similar phenotypes [2, 91, 92, 262, 210, 211, 182, 269, 270, 123, 93]. In hu-
mans this relationship can, for example, be observed in various inherited ataxias
[170]. These findings hint at the widespread association of protein complexes
with human disease and the likelihood that defects in several proteins, alone
or in combination, can cause overlapping clinical manifestations. Systematic
investigation of these complexes would help to elucidate cellular mechanisms
underlying various disorders and prioritize positional candidates identified, for
example, by linkage analysis or association studies.
Our strategy is predicated on the simple assumption that mutations in differ-
ent members of a protein complex (predicted from protein-protein interaction
data) lead to comparable phenotypes, the similarities of which can be automat-
ically recognized by text mining. Computational integration of phenotypic data
with a high-confidence interaction network of human proteins is required to per-
form such an analysis for many human diseases simultaneously. This creates a
phenome-interactome network. However, there is no single standard vocabulary
for phenotypic annotation in humans. Furthermore, protein interaction data
are noisy, are scattered among different databases and contain many false pos-
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itive interactions [276]. Additionally, only a few large-scale protein interaction
studies have been finalized for the human proteome [225, 249] rendering the
coverage of human protein interaction data too low for a systematic study of
protein complexes associated with human disease. Thus, extensive data inte-
gration, including conservative incorporation of protein interaction data from
model organisms, streamlining of human phenotype data and thorough testing
of the resulting method, is required for the systematic investigation of protein
complexes associated with human disease.
Results
Construction of a quality-controlled interaction network of human proteins and
implementation of a thoroughly benchmarked computational phenotype simi-
larity score allowed us to analyze a human phenome-interactome network. The
results show that the 506 disease-associated protein complexes span a wide range
of inherited disease categories. We furthermore trained a Bayesian predictor to
prioritize candidates in 870 linkage intervals by assigning candidates to protein
complexes and ranking these complexes based on the phenotypes associated with
its members by text mining. The key steps in our approach are illustrated in
Figure 1. Four disease-specific case studies are presented to illustrate how the
complexes can be exploited to generate novel hypotheses, which directly suggest
specific validation experiments involving particular patient-derived materials.
Measuring phenotype similarity scores
Text mining techniques are well suited for investigating phenotype-genotype re-
lationships [182, 123, 93, 268, 155, 232, 40]. Inspired by such techniques, we
created a scoring scheme that quantitatively measures the phenotypic overlap
of Online Mendelian Inheritance in Man (OMIM) [106] records (Supplementary
Fig. 1 online). For every record we created a phenotype vector consisting of
weighted medical terms present in the record, which represent the phenotype
described in that particular record. The parsing of the OMIM records was done
using MetaMap Transfer (MMTx) [8], a program that maps text to the Uni-
fied Medical Language System (UMLS) [33] metathesaurus (MTH) concepts.
The pairwise phenotypic overlap between records was quantified by calculating
the cosine of the angle between normalized vector pairs [229], which is a stan-
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dard measure in such analyses. Essentially, the method amounts to detecting
words (from the UMLS vocabulary) that are (i) common to the description of
the two phenotypes and (ii) do not occur too frequently among all phenotype
descriptions and thus are informative about the phenotype under consideration.
Even though our approach is comparable to successful methods reported in
other contexts [40], there are a number of problems surrounding the use of
MMTx and UMLS [70], and it is not obvious that the cosine distance between
phenotype vectors can accurately capture and quantify the phenotypic overlap
between record pairs. To evaluate the reliability of our method, we extracted a
large set of ˜7,000 OMIM record pairs, which had a high degree of phenotypic
overlap. This assertion of phenotypic overlap was based on a combination of the
opinion of expert OMIM curators and experts familiar with the diseases under
consideration (Supplementary Methods online). To evaluate the phenotypic
overlap of record pairs in this set, we manually curated 100 random record
pairs. This evaluation showed that over 90% of the pairs consist of records with
a high degree of phenotypic overlap (Supplementary Table 1 online).
The reliability of the phenotype similarity score was then tested by fitting a
calibration curve of the score against the overlap with the OMIM record pairs
(that is, the percentage of the pairs with a given score found among the record
pairs). This demonstrates their direct correlation (Supplementary Fig. 2 on-
line). The higher the phenotype similarity score between records measured by
our text-mining scheme, the higher the probability that the records had been
independently evaluated to have a phenotypic overlap by the OMIM curators,
so that indeed the constructed phenotype vectors and scoring scheme produce
a reliable measure of phenotypic overlap between OMIM records.
Constructing a scored network of human protein interac-
tions
We created a human protein interaction network by pooling human interaction
data from several of the largest databases and increased the coverage by trans-
ferring data from model organisms. We then devised and tested a network-wide
confidence score for all interactions. This score relies on network topology and
furthermore considers (i) that interactions from large-scale experiments gener-
ally contain more false positives than interactions from small-scale experiments
[276], and (ii) that interactions are more reliable if they have been reproduced
in more than one independent interaction experiment [276]. The reliability of
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this score as a measure of interaction confidence was confirmed by fitting a cal-
ibration curve of the score against overlap with a high-confidence set of about
35,000 human interactions (Supplementary Fig. 3 online). The resulting net-
work contains ˜343,000 unique interactions between ˜8,500 human proteins. Of
these, ˜62,000 are high-confidence interactions.
Testing the predictor on 1,404 linkage intervals
We trained a Bayesian predictor to rank known disease-causing proteins in link-
age intervals, by assigning candidates to protein complexes and ranking these
complexes based on the phenotypes assigned to their members by text min-
ing. The predictor was validated by fivefold cross-validation on a total of 1,404
linkage intervals containing an average of 109 candidates and including one can-
didate known to be involved in the particular disease. For ranking candidates,
the Bayesian predictor takes as input the patient phenotype (e.g., Leber con-
genital amaurosis) and a linkage interval, and the candidates are ranked by the
following three steps (Fig. 1). First, a given positional candidate is queried for
high-scoring interaction partners (termed a virtual pull-down of the protein).
These interaction partners compose the candidate complex. Second, proteins
known to be involved in disease are identified in the candidate complex, and
pairwise scores of the phenotypic overlap between diseases of these proteins and
the candidate phenotype are assigned. Third, based on the phenotypes rep-
resented in the candidate complex, the Bayesian predictor awards a posterior
probability score to the candidate in the complex. All candidates in the linkage
interval are ranked on the basis of this score. The biological interpretation of a
high-scoring candidate is that this protein is likely to be involved in the molec-
ular pathology of the disorder of interest, because it is part of a high-confidence
candidate complex in which some proteins are known to be involved in highly
similar (or identical) disorders.
Performance of the Bayesian model relying on phenomic
scoring of protein complexes associated to disease
The results of prioritizing candidates in the 1,404 test linkage intervals show
that the predictor has both good precision and recall (Fig. 2a). For each dis-
ease, we consider the known disease gene as the relevant gene. Our method
makes a prediction for a disease if the top scoring gene for this disease has a
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Steps in the scoring of each candidate in a linkage interval. 1) A virtual pull-
down of each candidate is made identifying putative protein complexes including
the candidate. This complex is named the candidate complex. 2) Proteins in-
volved in disease are identified in the candidate complex, using the computational
phenotype similarity score. In the figure proteins that are involved in different
disorders comparable to Leber congenital amaurosis are colored according to the
clinical overlap with this phenotype. 3) The last step is scoring and ranking of
the candidates based on the complexes by the Bayesian predictor.
score above the threshold of 0.1. This threshold is chosen because predictions
scoring below 0.1 approximate the random chance of picking the correct gene.
The retrieved gene is then this top scoring gene. Precision (at a given thresh-
old) is the proportion of relevant genes among all retrieved genes (# relevant
genes retrieved / # genes retrieved). Recall is the fraction of the relevant genes
that have been retrieved at the same threshold (# relevant genes retrieved / #
relevant genes). For the 1,404 linkage intervals, there are 669 different predic-
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tions with a score above 0.1. Among these there were 298 correctly identified
disease genes, so that the precision at this threshold is 45% (meaning that 45%
of the candidates that ranked number one with a score above 0.1 are the correct
disease gene) (Fig. 2a). This precision is much better than random. At this
threshold the recall is 21%. A plot of precision versus prediction score cutoff
shows proportionality between the score and the chance that the candidate is
correct. Candidates scoring above 0.9 are correct in more than 65% of the cases
(Fig. 2a). Thus, high scoring candidates are very likely to be correct, and the
score awarded to a candidate is a direct indication of the chance that the gene
is involved in the disease in question.
Performance of the Bayesian model relying on phenomic scoring of protein com-
plexes associated with disease The results of prioritizing candidates in the 1,404
test linkage intervals show that the predictor has both good precision and recall
(Fig. 2a). For each disease, we consider the known disease gene as the relevant
gene. Our method makes a prediction for a disease if the top-scoring gene for this
disease has a score above the threshold of 0.1. This threshold is chosen because
predictions scoring below 0.1 approximate the chance of picking the correct gene
randomly. The retrieved gene is then this top-scoring gene. Precision (at a given
threshold) is the proportion of relevant genes among all retrieved genes (no. of
relevant genes retrieved/no. of genes retrieved). Recall is the fraction of the
relevant genes that have been retrieved at the same threshold (no. of relevant
genes retrieved/no. of relevant genes). For the 1,404 linkage intervals, there are
669 different predictions with a score above 0.1. Among these, there were 298
correctly identified disease genes, so that the precision at this threshold is 45%
(that is, 45% of the candidates that ranked number one with a score above 0.1
are correctly identified as genes causing disease) (Fig. 2a) - a level of precision
far superior to random prediction. At this threshold, the recall is 21%. A plot of
precision versus prediction score cutoff shows proportionality between the score
and the chance that the candidate is correct. Candidates scoring above 0.9 are
correct in more than 65% of the cases (Fig. 2a). Thus, high-scoring candidates
are very likely to be correct, and the score awarded to a candidate is a direct
indication of the chance that the gene contributes to the disease in question.
There were two main types of failures to identify the relevant genes. Either the
proteins coded by the relevant genes do not have an interaction partner that is
involved in a relevant phenotype (which applies to 59% of all intervals), or there
is a gene in the region considered a better candidate by the predictor (which
applies to 26% of all intervals). These 26% could in theory be correct predic-
tions, as suggested by manual inspection of false predictions with high posterior
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probabilities. By far the most common failure is the lack of interaction partners
involved in similar diseases. In 75% of such cases there were no candidates that
scored above the threshold of 0.1. These failures could either be due to a lack of
data or because some disease proteins do not interact with proteins involved in
similar diseases. It seems most likely that the failures are due to a combination
of both.
We also tested a predictor trained on large-scale protein interaction data from
which bias related to human diseases was eliminated (Supplementary Methods
online). Here we observed a comparable precision to the predictor trained on
the full protein interaction data set (Fig. 2b). Using these data, the precision
above 0.1 is 25%, and above 0.9, it is 58%. Therefore, although the performance
is slightly lower, it is still very high. These results illustrate the value of large-
scale protein interaction data from model organisms, if subjected to stringent
quality control. The much lower recall (2.3%) is to be expected with less data.
This shows that it is possible to accurately identify disease genes using data
from model organisms that were not produced specifically to investigate disease
relationships.
Because mutational analysis of candidates in linkage intervals is extremely de-
manding in terms of resources, our method should be valuable for identifying
highly likely candidates and thereby facilitating the discovery of novel genes
involved in human disease.
Predicting novel disease gene candidates
OMIM contains 870 intervals linked to diseases for which there are no confirmed
disease-causing genes. We ranked the genes in these intervals by the method
depicted in Figure 1. The full set of predictions above the threshold of 0.1 can be
seen in the Supplementary Data. We present the best-scoring candidates made
by our predictor in Supplementary Table 2 online. In each of the 91 represented
intervals at least one candidate scores above 0.2. In some intervals there are also
candidates scoring in the range 0.1-0.2, these are included for completeness, so
the table contains a total of 113 candidates in 91 intervals.
All predictions in Supplementary Table 2 were followed up by independent lit-
erature studies, where we investigated the distance of the predicted gene to the
closest published high-resolution marker. Seven genes were located>20 Mb from
such markers (labeled * in Supplementary Table 2 online). We also investigated
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Benchmarking results. Prediction scores are plotted against fraction of true pos-
itives (a+b). For predictors trained on both sets of protein interaction data,
there is a comparable linear correlation between prediction score and fraction
true positive predictions, showing that the score is a reliable measure of predic-
tion accuracy. At scores > 0.9 the prediction accuracy is 65%. We also trained a
Bayesian predictor on unbiased large scale data alone (b), with a resulting speci-
ficity comparable to the one using all protein interaction data. Thus, bias in the
protein interaction data is not influencing specificity of the predictions.
whether the candidates had previously been associated with the respective dis-
orders, and whether there were inconsistencies between candidates we proposed
and those proposed by other groups for the same diseases and intervals.
Twenty-four of the predictions point to genes that are most likely true positives,
but where the causative mutation has not yet been identified (annotated with
”2” or ”2#” in Supplementary Table 2 online). In these cases, our predictions
should be seen as further evidence that the genes are involved in the respective
diseases. Seven predictions point to genes where a causative mutation has been
identified (annotated with ”3”in Supplementary Table 2 online). Together, these
constitute 31 predictions most likely to be true. Of these, 25 are the best scoring
in the interval, and 6 are scored second or lower. Sixteen predictions point to
genes for which literature studies show that a different gene is strongly incrim-
inated in the disease, most likely rendering the prediction wrong (annotated
with ”1#” in Supplementary Table 2 online). Of these, 11 are the best-scoring
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candidate in the interval and 5 score second or lower. When considering only
the best-scoring candidate in each interval (as we have done in the benchmark),
25 are most likely true positives and 11 are most likely negatives. Thus, the
precision is 69% - even better than the precision in the benchmark, where pre-
dictions above 0.2 have a precision of 49%. Sixty-six of the candidates belong
to intervals where there is no evidence in the literature regarding a gene(s) that
contributes to the pathology. We consider these as novel candidates. All com-
plexes underlying the candidates scoring 0.1 or above are available for download
from the database supporting this work.
To exemplify the candidate protein complexes underlying the scoring of the
Bayesian predictor, we present four case studies of the novel candidates from
Supplementary Table 2 online. Similar analysis can be carried out for all 506
complexes in the data set, pointing to specific approaches toward validation of
the proposed relationships.
Case studies
Retinitis pigmentosa is a clinically and genetically heterogeneous group of disor-
ders. Common traits are night blindness, constricted visual field and retinal dys-
trophy. In an associated interval on 2p15-p11 (ref. [105]), the Bayesian predictor
points to LOC130951 with a score of 0.5232. This protein is uncharacterized but
evolutionarily conserved, and it is putatively involved in the disease based on an
interaction with CRX25, [127] (Fig. 3a). CRX is a homeobox transcription fac-
tor known to be involved in retinitis pigmentosa and cone rod dystrophy [243].
The candidature of LOC130951 is not obvious, and because both interaction
studies reporting the interaction to CRX are large scale, including thousands
of interactions, it seems unlikely that LOC130951 would have been chosen as a
suitable candidate by manual investigation of the interval.
Epithelial ovarian cancer arises as a result of genetic alterations in the ovar-
ian surface epithelium. In an associated interval on 3p25-p22 (ref. [235]), the
Bayesian predictor points to Fanconi anemia group D2 protein (FANCD2) with
a score of 0.9981. This protein is placed in a complex with breast cancer type
2 susceptibility protein (BRCA2), breast cancer type 1 susceptibility protein
(BRCA1) and nibrin isoform 1 (NBN), all of which are involved in ovarian can-
cer, breast cancer or chromosomal instability disorders [66, 184, 46, 161] (Fig.
3b). Furthermore, other proteins involved in cancer can be identified in the
complex (Supplementary Data and Supplementary Fig. 4 online). FANCD2 is
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part of the BRCA pathway in cisplatin-sensitive cells [161] and is known to be
involved in different types of cancer [259]. However, to our knowledge, a muta-
tion in this gene has never been demonstrated in epithelial ovarian cancer, and
we consider it to be a likely candidate in epithelial ovarian cancer in families
with linkage to 3p22-p25.
Inflammatory bowel disease is characterized by chronic, relapsing intestinal in-
flammation. In an associated interval on 6p [65, 107], the Bayesian predictor
points to receptor-interacting serine/threonine protein kinase (RIPK1) as the
most likely candidate with a score of 0.9984 (Fig. 3c). The candidate complex
includes the signaling proteins tumor necrosis factor receptor 2 (TNFRSF1B),
tumor necrosis factor precursor (TNF) and tumor necrosis factor receptor pre-
cursor (TNFRSF1A), all known to be associated with inflammatory bowel dis-
ease or other inflammatory disorders. Furthermore, other proteins involved in
inflammation and immune responses can be observed in the complex (Supple-
mentary Data and Supplementary Fig. 5 online). We thus identified a posi-
tional candidate, which is placed centrally in a complex of proteins known to be
involved in inflammatory bowel disease and other types of inflammation. We
note that RIPK1 lies 20.6 Mb from the closest high-resolution marker published.
However, considering that all of 6q was screened for candidates, and that several
genes lying far from the published markers are most likely true predictions in
Supplementary Table 2 online, we believe that RIPK1 is a very likely candidate
involved in inflammatory bowel disease.
Amyotrophic lateral sclerosis (ALS) with frontotemporal dementia is a degener-
ative motor neuron disorder characterized by muscular atrophy, progressive mo-
tor neuron function loss and bulbar paralysis. In many families, hereditary ALS
is associated with frontotemporal dementia and linkage has been shown to an
area on 9q21-q22 (ref. [122]). Here, the Bayesian predictor points to two likely
candidates: bicaudal D homolog 2 (BICD2) and cytoplasmic isoleucyl-tRNA
synthetase (IARS), scoring 0.4351 and 0.2154, respectively. Although BICD2
is scored highest, both candidates are awarded good scores and are plausible
candidates for contributing to ALS associated with dementia. However, inves-
tigation of the candidate complexes suggests that BICD2 is more likely to be
involved in non-familial ALS not associated with dementia, because it is part
of a complex with dynactin, which is associated with ALS without dementia.
IARS is in a complex with superoxide dismutase 1, a protein known to be in-
volved in familial ALS47 including dementia (Fig. 3d). Also, the IARS complex
contains molecular chaperones and other proteins that have been connected to
the disease and other types of dementias (Supplementary Fig. 6 online), and the
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interaction data underlying the complex is highly reproducible (Supplementary
Data online). Both candidates are likely, but the candidate complex underlying
IARS is seemingly more relevant to familial ALS, and it is plausible that IARS
could be involved in the disease in families with linkage to 9q21-q22. Because
little is known about this disorder, the complex revealed here is an interesting
new lead concerning its underlying causes.
These case studies indicate the value of data mining our phenome-interactome
network and integrating interaction data across multiple organisms for posi-
tional candidate prioritization. In the case of retinitis pigmentosa and ALS
with frontotemporal dementia, the predictor identifies non obvious candidates
in novel putative complexes supported by a network of reproducible interaction
data from humans and multiple model organisms. In the cases of inflammatory
bowel disease and epithelial ovarian cancer, we identify partly characterized
complexes, where several members are known to be involved in the patient phe-
notype. However, because there are ˜500 positional candidates in the case of
inflammatory bowel disease, it would require extensive literature studies to re-
veal this network and candidate by manual data integration. We thus believe
that RIPK1 would probably not have been identified as a good candidate de-
spite prior knowledge of its involvement in a known network contributing to
inflammatory responses.
DISCUSSION
We have recently witnessed the emergence of integrative methods for identifying
probable disease genes in linkage intervals associated with disease based on data
integration involving, for example, Gene Ontology categories and expression
data [2, 91, 92, 262, 210, 211, 182, 269, 270, 123, 93]. Traditionally these methods
are compared by measuring average fold enrichment of positional probability
(Supplementary Methods online). If a method ranks the true candidate in the
top 10% of all candidates in 50% of the linkage intervals, there is a tenfold
enrichment in the successful predictions intervals and fivefold enrichment on
average. We show that our method increases the probability 108.8 times for the
successful predictions and 23.1 times on average, significantly outperforming
the other computational methods for positional candidate prioritization, which
report 5.6-31.2 times enrichment in the successful linkage intervals to 3.8 to
19.4 times enrichment on average (Supplementary Table 3 online). The most
common failure of our method to correctly identify the disease gene results from
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the inability to find interaction partners associated with a similar phenotype as
the relevant protein. This could result from either a lack of data or the failure of
these proteins to interact with proteins involved in similar phenotypes. In 75%
of these cases, failure to identify another candidate scoring over 0.1 eliminates
the possibility of an incorrect prediction.
Our ability to assign candidates to high-confidence protein complexes and rank
these complexes in terms of phenomics has permitted us to present a first draft
of 506 protein complexes associated with human disease. The success of our
method can be attributed to a combination of factors. First, we integrate ex-
perimental protein interaction data with a phenotype similarity scheme, thereby
taking advantage of the complete clinical spectrum of related human diseases.
Also, we use high-confidence protein complexes for identifying novel candidates,
thus ensuring that we take advantage of the full protein network context of the
candidate, which we show is well suited for functional association of proteins
with diseases. Only three of the previously published methods use protein inter-
action data [91, 203, 3]. Whereas one [203] relies completely on unscored binary
interaction pairs to identify candidates in identical diseases, others [91, 3] incor-
porate unscored human protein interaction data as one of the weaker sources
of information. The two latter methods do not take advantage of cross-species
integration of interaction data and none of the three integrate phenotypic de-
scriptions as we have done. Furthermore, two approaches [203, 91] search only
for candidates implicated in identical diseases and do not take advantage of in-
formation from different diseases with a phenotypic overlap. Another method22
relies on provision of a training set and could theoretically be trained using
proteins involved in non identical but overlapping phenotypes. These methods
report 10.0-15.4 times enrichment in the successful linkage intervals and 5.0-
10.0 times enrichment on average (Supplementary Table 3 online). All three
methods are innovative and of high quality, but the difference in performance
can readily be explained by recalling that the use of high-confidence protein
complexes and data about overlapping phenotypes is much better at inferring
functional associations than the search for unscored single-interaction partners
involved in identical phenotypes only. The complexes generated in the training
and validation of the method provide a valuable resource for further investiga-
tions by researchers investigating these diseases, because the complexes place
the disease-causing proteins in a functional context relative to other disease-
associated proteins. We have created a database of these two data sets (available
from http://www.cbs.dtu.dk/suppl/dgf/) providing a draft of 506 putative
human disease complexes, determined by the current resolution of data. Our
120
4.3. Paper IV: A human phenome-interactome network of protein complexes
in genetic disorders
validation shows that the score associated with each complex can be used as a
reliable indication of the quality of the data underlying the complex.
METHODS
Design choices of the Bayesian predictor.
We have strived to make optimal design choices to guarantee the quality of the
methodology. First, for the phenotype similarity score, we opted for the UMLS
vocabulary, because it is a well-known resource for this type of analysis, and
MMTx for the term mapping. There are some limitations when using MMTx
and UMLS (see Supplementary Methods online), but we concluded that these
are well suited for our analysis, and improvement of these resources is beyond
the scope of this work. Second, we chose term frequency-inverse document fre-
quency (tf-idf) as the term-weighting strategy. Compared with unweighted vec-
tors and idf term weighting, tf-idf performed better (Supplementary Fig. 7 on-
line). Third, we used the cosine similarity measure between phenotype vectors,
because it is a well-accepted similarity measure for weighted-term vectors. We
demonstrate the robustness of this measure on phenotype vectors constructed
from a different text source, weighting method and vocabulary (Supplementary
Fig. 8 online). Finally, for reporting likely candidates, a threshold of 0.1 on the
Bayesian score was chosen on the basis of our benchmark. Using these design
choices we created a Bayesian model that was trained and validated using five-
fold cross-validation. Additionally, the model was thoroughly optimized to get
the optimal separation of signal to noise from the phenotype similarity scheme,
the protein interaction data and the other parameters in the model. This was
done using a genetic algorithm (Supplementary Methods online).
Filtering irrelevant semantic types from UMLS.
The UMLS vocabulary was manually checked for semantic types that were obvi-
ously not clinically relevant (for example, STY|T066|Machine Activity, STY|T068|Human-
caused Phenomenon or Process, STY|T093|Health Care Related Organization,
STY|T097|Professional or Occupational Group). Terms belonging to these se-
mantic types were filtered out and do not appear in the phenotype vectors. This
procedure helps in limiting the phenotype vectors to relevant medical terms to
as large an extent as possible.
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Phenotype similarity scores.
Both the text and clinical synopsis parts of each OMIM record were parsed with
MMTx (http://mmtx.nlm.nih.gov/) (for a discussion on the recall, precision
and well documented problems of MMTx see Supplementary Methods online)
to find the occurrence of medical terms in a subset of the UMLS vocabulary
[33], where a number of obviously non clinical semantic type categories had
been removed. Phenotype vectors for each record were constructed so that the
value of each dimension in the vector represents the number of occurrences of
that term in that particular record. Because many relevant terms (for example,
mental retardation) are very frequent in OMIM, we also assigned a weight to
every extracted term in a phenotype vector. This was done by comparing the
frequency with which the term was used in the record in question to its mention
the term in all records (that is, all of OMIM). This weight is called tf-idf [212]
(Supplementary Methods online) and markedly improves the predictive qual-
ity of the data (Supplementary Methods online). Furthermore, this procedure
normalizes the term weight using the length of the specific record and the to-
tal length of all records. This normalization reduces negative bias in relation
to short records, and positive bias in relation to long records. Once vectors
for all records had been constructed, pairwise similarity was calculated as the
cosine of the angle between the OMIM vectors after normalization [229]. We
used the cosine measure as a natural similarity score for two vectors, because
it is a standard measure used in this type of text-mining analysis and it is fast
to calculate. We note a small bias against some of the phenotype vectors used
to predict because of less well curated and described phenotype records in the
prediction set than in the benchmarking set (Supplementary Table 4 online).
We believe this bias is largely caused by less extensive annotation by the OMIM
curators of records describing loci where the disease gene has not been identified.
The result is fewer predictions than expected from the benchmark. However, it
is important to note that the predictions we do get are of equal quality to the
benchmarking case, because the posterior probability score relies on the quality
of the data used for the prediction.
Validating the phenotype similarity score.
To investigate to what extent our phenotype vector cosine scores could correctly
assign phenotype similarity between scored records, we fitted a curve of the score
against the overlap in OMIM record pairs that had a high degree of phenotypic
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overlap (Supplementary Methods online). The curve shows that the compu-
tational phenotype similarity score is directly correlated to the probability of
overlap with these record pairs (Supplementary Fig. 2 online)
Constructing a scored human protein interaction network.
Protein interaction data were downloaded from MINT [296], BIND [11], IntAct
[117], KEGG annotated protein-protein interactions (PPrel), KEGG Enzymes
involved in neighboring steps (ECrel) [144] and Reactome proteins involved in
the same complex, indirect complex, reaction or neighboring reaction [141]. All
human data were pooled, and to increase the coverage of interactions, interolog
data (the transfer of protein interactions between orthologous protein pairs in
different organisms) [278] were included by a method similar to that reported
by Lehner and Fraser [168]. Interactions were transferred from 17 eukaryotic
organisms and added to the network. Orthology was assigned using the In-
paranoid database [199] with strict thresholds. To obtain a global interaction
score for all interactions in the network, we constructed a probabilistic protein
interaction score that took into account the topology of the interaction network
surrounding the interaction, the experimental setup (large-scale vs. small-scale)
and the number of different publications in which the interaction had been de-
tected (Supplementary Methods online).
Making a virtual pull-down.
A virtual pull-down of a given protein was done by querying the interaction
network for all interactions of the protein (and subsequently all interactions
between the interacting proteins) and only retaining the interactions over a
given score threshold as defined by the genetic algorithm in the training steps
of the Bayesian predictor. This means that the resulting interactions all are
of high confidence and supported by network topology, different publications,
reliable small-scale interaction experiments, reproducibility or a combination of
these.
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Identifying proteins involved in diseases in the candidate complexes.
Ensembl Mart(http://dec2005.archive.ensembl.org/Multi/martview) was
used to associate proteins to phenotypes (MIMS) and identify proteins involved
in disease in the candidate complexes.
Making the benchmarking cases.
A list of 3,256 disease genes was initially downloaded from the Disease Gene ta-
ble in GeneCards (http://nciarray.nci.nih.gov/cards/). GeneCards mines
several different databases, including OMIM, for text describing the disease
genes in this table. For some of the disease genes the entries in GeneCards are
sentences, originating from OMIM, specifically stating that defects in particular
genes lead to particular diseases. To exclude genes associated to diseases by
circumstantial evidence, and only include genes in which genetic defects were
known to be causative in relation to the particular disorders, we included genes
in the benchmarking set only if GeneCards had found such sentences in OMIM in
relation to the gene. Because OMIM is a database manually curated by disease
experts, we consider such statements from OMIM to be trustworthy. However,
to double-check that no mistakes were made by GeneCards in the extraction pro-
cedure, or in the curation process by OMIM, we randomly selected 50 of these
statements and manually checked (i) that such statements were actually present
in the relevant OMIM files and (ii) that the statements were supported by cited
literature. In these 50 cases no discrepancies were found, and this investigation
led us to consider that all of the statements are correct. This procedure led to a
subset of 963 genes and their corresponding proteins. These genes and proteins
were associated with their respective phenotypes using GeneCards references to
OMIM diseases. This showed that the 963 genes are involved in 1,404 distinct
phenotypes, which were used for the training and validation of the Bayesian
predictor. Benchmarking cases were made by associating the genes to distinct
phenotypes using the annotation in GeneCards and by assigning the genes to
artificial linkage intervals. This was done by including a random number of
genes upstream and downstream of the known disease gene. The interval sizes
were randomized so that they have a distribution similar to the intervals in
OMIM morbidmap, for which no gene has been identified, leading to an average
of 108.8 genes in each of the 1,404 linkage intervals.
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Training and validating the Bayesian model.
Training and benchmarking of the Bayesian model were done by fivefold cross-
validation on the benchmarking set. The set of 1,404 benchmarking cases was
split into five sets and the Bayesian model trained and optimized on four of
these fractions (Supplementary Methods online). Subsequently, the optimized
model was used to rank candidates in benchmarking cases made on the last fifth
of the data set. This was done for all combinations of the five fractions. The
benchmarking results can be seen in Supplementary Table 5 online.
Bayesian disease gene predictor.
The goal is to compute, for each candidate in a critical interval, the probability
that this is the disease-related protein. High probabilities should be assigned
to candidates that interact with one or more proteins involved in disorders that
are phenotypically similar to the one being investigated. This logic is expressed
in the form of a probabilistic model and we use Bayes’ theorem to compute
the probabilities. The model includes parameters for (1) the probability that a
candidate protein has any reported interaction partners, (2) protein interaction
score, (3) the number of interaction partners that are involved in similar dis-
orders, and (4) computational phenotype similarity score. All parameters are
estimated from our data sets for both disease- and non-disease-associated genes,
where we see that the parameter values are different in the two cases. The prob-
ability, that protein number i (among N candidates) is the disease associated
one, is computed as follows:
P (dis = i|DATA) =
P (DATA|dis = i)× P (dis = i)
∑N
j=1 P (DATA|dis = j)× P (dis = j)
Where P (dis = i|DATA) is the posterior probability that candidate number
i is the disease-related protein after evaluating all the data. P (dis = i) is
the prior probability that candidate number i is the disease causing protein,
before evaluating any data. The prior value was set to 1
N
for all candidates.
The term P (DATA|dis = i) is the probability of value was set to obtaining
the observed data if candidate number i was in fact the correct one. This
likelihood is computed from the interaction data and any associated phenotype
descriptions, and using the estimated parameters, in a straightforward manner
(Supplementary Materials on-line).
125
Chapter 4. Networks
Case studies.
Case studies were made by downloading complex data available for all putative
disease complexes (http://www.cbs.dtu.dk/suppl/dgf/) and creating an in-
teractive graph in the free software cytoscape (http://www.cytoscape.org/).
Data in these files combined with literature studies were used to generate the hy-
potheses. More data on the case studies can be found in (Supplementary Mate-
rial online). Proteins are named by using the corresponding gene name according
to HUGO gene nomenclature http://www.gene.ucl.ac.uk/nomenclature/.
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Figure 3: Case studies of four candidate complexes. These candidate complexes
are virtually pulled-down with the best scoring candidate in retinitis pigmentosa
28 (RP28) (a), epithelial ovarian cancer (EOC) (b), inflammatory bowel disease
(IBD) (c) and a high scoring candidate in amyotrophic lateral sclerosis (ALS)
with frontotemporal dementia (d), respectively. The black proteins (C) are the
high scoring candidates in the four disorders, numbered proteins are proteins
interacting with the candidate proteins. Colored nodes are proteins identified
by our phenotype association scheme, and grey proteins are not known to be
involved in the disorder.
127
Chapter 4. Networks
128
Chapter 5
Epilogue
129
Chapter 5. Epilogue
Reading the complete thesis, it may sound as if the 3 years I spent at CBS
working on these projects was a completely planned and coordinated effort. In
reality that is far from the truth, as I suppose is true for most research.
My main focus through the duration of my Ph.D. was always protein-protein
interaction prediction. The work on Internet technologies and data sharing
standards in chapter 2 is a result of CBS responsibilities as a part of BioS-
apiens NoE. Implementing the distributed annotation system (DAS) in various
proteomics labs around Europe opened the possibility of integrated functional
research of the ENCODE complement (section 2.1.3), where analysis of splice
variants yielded surprising results about the functional and structural diversity
of gene products from individual loci. Computational analysis from a dozen labs
around Europe were performed and integrated in a matter of days, yet again
proving the importance of being on line today.
When our attempts at protein-protein interaction (PPI) prediction did not bear
anticipated fruits, we looked more into the practical use of PPI data, looking
globally at the resulting interactome instead of individual interactions. Espe-
cially we focused on chromosomal interaction maps to see if we could find links
between interaction networks and the ability to survive trisomy. I became a part
of a disease gene finding project, which focused on PPI data. In that framework
we successfully attached phenotype annotations to the network of interactions
to identify genes with disease phenotypes.
Diseases with a simple Mendelian inheritance model, such as cystic fibrosis and
Huntington’s disease are rare. In the case of complex diseases there are several
genes/proteins whose specific alleles incrementally add to the risk of developing
the disease. Diabetes is one such disease where a suspected 5-10 (or even more)
genes are involved [57]. Despite ever higher genotype resolutions, ever faster
sequencing techniques, linking disease phenotypes and specific genes continues to
be a tough task, one where systems biology may provide valuable understanding
by identifying complex relationships between the genes implicated in a particular
disease [153]. One field where there is room for considerable improvements is
phenomics. The success of the simple phenotype vector assignment-and-overlap
framework, used to identify related genetic diseases in section 4.3 shows the
possibilities for use and integration of such data in biology. The disease gene
finding effort proves that the amount of data being generated by high throughput
experiments has reached critical mass for systems biology and that the resulting
networks are now saturated enough for practical use. The ultimate target is a
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future where we, not just understand the complex systems within the cell, but
rather are able to manipulate these with precision bioengineering.
High throughput experiments are not only allowing us to analyse data in a
systems fashion. Being able to integrate data in such way helps us to identify
the pieces that stand out and to go back and scrutinise the those pieces. The
genome sequence has already been uncovered, and as 99.9% of it is identical in
us all, we have to look elsewhere for the cause of variation in phenotype and
disease. Recent studies indicate that quantitative experiments of expression
may hold the key to our phenotypes, both with regard to regulation [245] and
copy number variation in DNA [218]. Analyses of primary sequence are not yet
yielding answers to all the whys, but rather pointing to new paths to explore.
Therefore we hope for systems biology to bridge the gap between genotype and
phenotype. There is a lot of work to be done but we are certainly making
progress.
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